BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Case JB, Rothlauf PW, Chen RE, Liu Z, Zhao H, Kim AS, Bloyet LM, Zeng Q, Tahan S, Droit L, Ilagan MXG, Tartell MA, Amarasinghe G, Henderson JP, Miersch S, Ustav M, Sidhu S, Virgin HW, Wang D, Ding S, Corti D, Theel ES, Fremont DH, Diamond MS, Whelan SPJ. Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. Cell Host Microbe 2020;28:475-485.e5. [PMID: 32735849 DOI: 10.1016/j.chom.2020.06.021] [Cited by in Crossref: 140] [Cited by in F6Publishing: 214] [Article Influence: 70.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang K, Wang C, Kreutzberger AJB, Ojha R, Kuivanen S, Couoh-Cardel S, Muratcioglu S, Eisen TJ, White KI, Held RG, Subramanian S, Marcus K, Pfuetzner RA, Esquivies L, Doyle CA, Kuriyan J, Vapalahti O, Balistreri G, Kirchhausen T, Brunger AT. Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein. Proc Natl Acad Sci U S A 2022;119:e2210990119. [PMID: 36122200 DOI: 10.1073/pnas.2210990119] [Reference Citation Analysis]
2 Ratnapriya S, Braun AR, Cervera Benet H, Carlson D, Ding S, Paulson CN, Mishra N, Sachs JN, Aldrich CC, Finzi A, Herschhorn A. Broad Tricyclic Ring Inhibitors Block SARS-CoV-2 Spike Function Required for Viral Entry. ACS Infect Dis 2022. [PMID: 36153947 DOI: 10.1021/acsinfecdis.1c00658] [Reference Citation Analysis]
3 Kreutzberger AJB, Sanyal A, Saminathan A, Bloyet LM, Stumpf S, Liu Z, Ojha R, Patjas MT, Geneid A, Scanavachi G, Doyle CA, Somerville E, Correia RBDC, Di Caprio G, Toppila-Salmi S, Mäkitie A, Kiessling V, Vapalahti O, Whelan SPJ, Balistreri G, Kirchhausen T. SARS-CoV-2 requires acidic pH to infect cells. Proc Natl Acad Sci U S A 2022;119:e2209514119. [PMID: 36048924 DOI: 10.1073/pnas.2209514119] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Borgogna C, Bruna R, Griffante G, Martuscelli L, De Andrea M, Ferrante D, Patriarca A, Mahmoud AM, Ucciero MAM, Gaidano V, Marchetti M, Rapezzi D, Lai M, Pistello M, Ladetto M, Massaia M, Gaidano G, Gariglio M. Induction of robust humoral immunity against SARS-CoV-2 after vaccine administration in previously infected haematological cancer patients. Br J Haematol 2022. [PMID: 36062472 DOI: 10.1111/bjh.18429] [Reference Citation Analysis]
5 Walls AC, VanBlargan LA, Wu K, Choi A, Navarro MJ, Lee D, Avena L, Berrueta DM, Pham MN, Elbashir S, Kraft JC, Miranda MC, Kepl E, Johnson M, Blackstone A, Sprouse K, Fiala B, O'Connor MA, Brunette N, Arunachalam PS, Shirreff L, Rogers K, Carter L, Fuller DH, Villinger F, Pulendran B, Diamond MS, Edwards DK, King NP, Veesler D. Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice. Cell Rep 2022;40:111299. [PMID: 35988541 DOI: 10.1016/j.celrep.2022.111299] [Reference Citation Analysis]
6 Crunfli F, Carregari VC, Veras FP, Silva LS, Nogueira MH, Antunes ASLM, Vendramini PH, Valença AGF, Brandão-Teles C, Zuccoli GDS, Reis-de-Oliveira G, Silva-Costa LC, Saia-Cereda VM, Smith BJ, Codo AC, de Souza GF, Muraro SP, Parise PL, Toledo-Teixeira DA, Santos de Castro ÍM, Melo BM, Almeida GM, Firmino EMS, Paiva IM, Silva BMS, Guimarães RM, Mendes ND, Ludwig RL, Ruiz GP, Knittel TL, Davanzo GG, Gerhardt JA, Rodrigues PB, Forato J, Amorim MR, Brunetti NS, Martini MC, Benatti MN, Batah SS, Siyuan L, João RB, Aventurato ÍK, Rabelo de Brito M, Mendes MJ, da Costa BA, Alvim MKM, da Silva Júnior JR, Damião LL, de Sousa IMP, da Rocha ED, Gonçalves SM, Lopes da Silva LH, Bettini V, Campos BM, Ludwig G, Tavares LA, Pontelli MC, Viana RMM, Martins RB, Vieira AS, Alves-Filho JC, Arruda E, Podolsky-Gondim GG, Santos MV, Neder L, Damasio A, Rehen S, Vinolo MAR, Munhoz CD, Louzada-Junior P, Oliveira RD, Cunha FQ, Nakaya HI, Mauad T, Duarte-Neto AN, Ferraz da Silva LF, Dolhnikoff M, Saldiva PHN, Farias AS, Cendes F, Moraes-Vieira PMM, Fabro AT, Sebollela A, Proença-Modena JL, Yasuda CL, Mori MA, Cunha TM, Martins-de-Souza D. Morphological, cellular, and molecular basis of brain infection in COVID-19 patients. Proc Natl Acad Sci U S A 2022;119:e2200960119. [PMID: 35951647 DOI: 10.1073/pnas.2200960119] [Reference Citation Analysis]
7 Tioni MF, Jordan R, Pena AS, Garg A, Wu D, Phan SI, Weiss CM, Cheng X, Greenhouse J, Orekov T, Valentin D, Kar S, Pessaint L, Andersen H, Stobart CC, Bloodworth MH, Stokes Peebles R, Liu Y, Xie X, Shi PY, Moore ML, Tang RS. Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2. NPJ Vaccines 2022;7:85. [PMID: 35906244 DOI: 10.1038/s41541-022-00509-6] [Reference Citation Analysis]
8 LeBlanc EV, Colpitts CC. The green tea catechin EGCG provides proof-of-concept for a pan-coronavirus attachment inhibitor. Sci Rep 2022;12:12899. [PMID: 35902713 DOI: 10.1038/s41598-022-17088-0] [Reference Citation Analysis]
9 Manangeeswaran M, Ireland DDC, Thacker SG, Lee H, Kelley-baker L, Lewkowicz AP, Rothlauf PW, Cornejo Pontelli M, Bloyet L, Eckhaus MA, Mendoza MI, Whelan S, Verthelyi D. BSL2-compliant lethal mouse model of SARS-CoV-2 and variants of concern to evaluate therapeutics targeting the Spike protein. Front Immunol 2022;13:919815. [DOI: 10.3389/fimmu.2022.919815] [Reference Citation Analysis]
10 Bowen JE, Addetia A, Dang HV, Stewart C, Brown JT, Sharkey WK, Sprouse KR, Walls AC, Mazzitelli IG, Logue JK, Franko NM, Czudnochowski N, Powell AE, Dellota E Jr, Ahmed K, Ansari AS, Cameroni E, Gori A, Bandera A, Posavad CM, Dan JM, Zhang Z, Weiskopf D, Sette A, Crotty S, Iqbal NT, Corti D, Geffner J, Snell G, Grifantini R, Chu HY, Veesler D. Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. Science 2022;:eabq0203. [PMID: 35857529 DOI: 10.1126/science.abq0203] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
11 Callegari I, Schneider M, Berloffa G, Mühlethaler T, Holdermann S, Galli E, Roloff T, Boss R, Infanti L, Khanna N, Egli A, Buser A, Zimmer G, Derfuss T, Sanderson NSR. Potent neutralization by monoclonal human IgM against SARS-CoV-2 is impaired by class switch. EMBO Rep 2022;23:e53956. [PMID: 35548920 DOI: 10.15252/embr.202153956] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Labriola JM, Miersch S, Chen G, Chen C, Pavlenco A, Saberianfar R, Caccuri F, Zani A, Sharma N, Feng A, Leung DW, Caruso A, Novelli G, Amarasinghe GK, Sidhu SS. Peptide-Antibody Fusions Engineered by Phage Display Exhibit an Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants. ACS Chem Biol 2022. [PMID: 35731947 DOI: 10.1021/acschembio.2c00411] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kramer KJ, Wilfong EM, Voss K, Barone SM, Shiakolas AR, Raju N, Roe CE, Suryadevara N, Walker LM, Wall SC, Paulo A, Schaefer S, Dahunsi D, Westlake CS, Crowe JE Jr, Carnahan RH, Rathmell JC, Bonami RH, Georgiev IS, Irish JM. Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine. Nat Commun 2022;13:3466. [PMID: 35710908 DOI: 10.1038/s41467-022-31142-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Cugno M, Meroni PL, Consonni D, Griffini S, Grovetti E, Novembrino C, Torri A, Griffante G, Gariglio M, Varani L, Peyvandi F. Effects of Antibody Responses to Pre-Existing Coronaviruses on Disease Severity and Complement Activation in COVID-19 Patients. Microorganisms 2022;10:1191. [PMID: 35744709 DOI: 10.3390/microorganisms10061191] [Reference Citation Analysis]
15 Hong Y, Guo H, Wei M, Zhang Y, Fang M, Cheng T, Li Z, Ge S, Yao X, Yuan Q, Xia N. Cell-based reporter assays for measurements of antibody-mediated cellular cytotoxicity and phagocytosis against SARS-CoV-2 spike protein. J Virol Methods 2022;:114564. [PMID: 35671888 DOI: 10.1016/j.jviromet.2022.114564] [Reference Citation Analysis]
16 Zou J, Xia H, Shi P, Xie X, Ren P. A Single-Round Infection Fluorescent SARS-CoV-2 Neutralization Test for COVID-19 Serological Testing at a Biosafety Level-2 Laboratory. Viruses 2022;14:1211. [DOI: 10.3390/v14061211] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Suryadevara N, Gilchuk P, Zost SJ, Mittal N, Zhao LL, Crowe JE, Carnahan RH. Real-time cell analysis: A high-throughput approach for testing SARS-CoV-2 antibody neutralization and escape. STAR Protocols 2022;3:101387. [DOI: 10.1016/j.xpro.2022.101387] [Reference Citation Analysis]
18 Lichtenegger S, Saiger S, Hardt M, Kulnik S, Wagner GE, Kleinhappl B, Assig K, Zauner A, Ober M, Kimpel J, von Laer D, Zatloukal K, Steinmetz I. Development of a Rapid Live SARS-CoV-2 Neutralization Assay Based on a qPCR Readout. J Clin Microbiol 2022;:e0037622. [PMID: 35642515 DOI: 10.1128/jcm.00376-22] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Bamunuarachchi G, Harastani H, Rothlauf PW, Dai YN, Ellebedy A, Fremont D, Whelan SPJ, Wang D, Boon ACM. Detection of Bourbon Virus-Specific Serum Neutralizing Antibodies in Human Serum in Missouri, USA. mSphere 2022;:e0016422. [PMID: 35607948 DOI: 10.1128/msphere.00164-22] [Reference Citation Analysis]
20 Puray-chavez M, Lee N, Tenneti K, Wang Y, Vuong HR, Liu Y, Horani A, Huang T, Gunsten SP, Case JB, Yang W, Diamond MS, Brody SL, Dougherty J, Kutluay SB, Jurado K. The Translational Landscape of SARS-CoV-2-infected Cells Reveals Suppression of Innate Immune Genes. mBio. [DOI: 10.1128/mbio.00815-22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Grigoryan L, Lee A, Walls AC, Lai L, Franco B, Arunachalam PS, Feng Y, Luo W, Vanderheiden A, Floyd K, Wrenn S, Pettie D, Miranda MC, Kepl E, Ravichandran R, Sydeman C, Brunette N, Murphy M, Fiala B, Carter L, Coffman RL, Novack D, Kleanthous H, O'Hagan DT, van der Most R, McLellan JS, Suthar M, Veesler D, King NP, Pulendran B. Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice. NPJ Vaccines 2022;7:55. [PMID: 35606518 DOI: 10.1038/s41541-022-00472-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Liu H, Wilson IA. Protective neutralizing epitopes in SARS‐CoV‐2. Immunological Reviews. [DOI: 10.1111/imr.13084] [Reference Citation Analysis]
23 Karvas RM, Khan SA, Verma S, Yin Y, Kulkarni D, Dong C, Park KM, Chew B, Sane E, Fischer LA, Kumar D, Ma L, Boon ACM, Dietmann S, Mysorekar IU, Theunissen TW. Stem-cell-derived trophoblast organoids model human placental development and susceptibility to emerging pathogens. Cell Stem Cell 2022;29:810-825.e8. [PMID: 35523141 DOI: 10.1016/j.stem.2022.04.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
24 Lin J, Tien C, Kuo Y, Lin E, Tsai W, Chen M, Tsai P, Su Y, Pathak N, Yang J, Yu C, Chuang Z, Wu H, Tsai W, Dai S, Liao H, Chai KM, Su Y, Chuang T, Liu S, Chen H, Dou H, Chen F, Chen C, Liao C, Yu G. Furin and TMPRSS2 Resistant Spike Induces Robust Humoral and Cellular Immunity Against SARS-CoV-2 Lethal Infection. Front Immunol 2022;13:872047. [DOI: 10.3389/fimmu.2022.872047] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ying B, Scheaffer SM, Whitener B, Liang CY, Dmytrenko O, Mackin S, Wu K, Lee D, Avena LE, Chong Z, Case JB, Ma L, Kim TTM, Sein CE, Woods A, Berrueta DM, Chang GY, Stewart-Jones G, Renzi I, Lai YT, Malinowski A, Carfi A, Elbashir SM, Edwards DK, Thackray LB, Diamond MS. Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. Cell 2022;185:1572-1587.e11. [PMID: 35452622 DOI: 10.1016/j.cell.2022.03.037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
26 Servellita V, Syed AM, Morris MK, Brazer N, Saldhi P, Garcia-Knight M, Sreekumar B, Khalid MM, Ciling A, Chen PY, Kumar GR, Gliwa AS, Nguyen J, Sotomayor-Gonzalez A, Zhang Y, Frias E, Prostko J, Hackett J Jr, Andino R, Wadford DA, Hanson C, Doudna J, Ott M, Chiu CY. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. Cell 2022;185:1539-1548.e5. [PMID: 35429436 DOI: 10.1016/j.cell.2022.03.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
27 Okuya K, Hattori T, Saito T, Takadate Y, Sasaki M, Furuyama W, Marzi A, Ohiro Y, Konno S, Hattori T, Takada A. Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection. Microbiol Spectr 2022;10:e0155321. [PMID: 35319248 DOI: 10.1128/spectrum.01553-21] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
28 Sheikh-mohamed S, Isho B, Chao GYC, Zuo M, Cohen C, Lustig Y, Nahass GR, Salomon-shulman RE, Blacker G, Fazel-zarandi M, Rathod B, Colwill K, Jamal A, Li Z, de Launay KQ, Takaoka A, Garnham-takaoka J, Patel A, Fahim C, Paterson A, Li AX, Haq N, Barati S, Gilbert L, Green K, Mozafarihashjin M, Samaan P, Budylowski P, Siqueira WL, Mubareka S, Ostrowski M, Rini JM, Rojas OL, Weissman IL, Tal MC, Mcgeer A, Regev-yochay G, Straus S, Gingras A, Gommerman JL. Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. Mucosal Immunol. [DOI: 10.1038/s41385-022-00511-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 16.0] [Reference Citation Analysis]
29 Hunt AC, Case JB, Park YJ, Cao L, Wu K, Walls AC, Liu Z, Bowen JE, Yeh HW, Saini S, Helms L, Zhao YT, Hsiang TY, Starr TN, Goreshnik I, Kozodoy L, Carter L, Ravichandran R, Green LB, Matochko WL, Thomson CA, Vögeli B, Krüger A, VanBlargan LA, Chen RE, Ying B, Bailey AL, Kafai NM, Boyken SE, Ljubetič A, Edman N, Ueda G, Chow CM, Johnson M, Addetia A, Navarro MJ, Panpradist N, Gale M Jr, Freedman BS, Bloom JD, Ruohola-Baker H, Whelan SPJ, Stewart L, Diamond MS, Veesler D, Jewett MC, Baker D. Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice. Sci Transl Med 2022;:eabn1252. [PMID: 35412328 DOI: 10.1126/scitranslmed.abn1252] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
30 Yu X, Wei D, Xu W, Liu C, Guo W, Li X, Tan W, Liu L, Zhang X, Qu J, Yang Z, Chen E. Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-29477-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
31 Maza MDC, Úbeda M, Delgado P, Horndler L, Llamas MA, van Santen HM, Alarcón B, Abia D, García-bermejo L, Serrano-villar S, Bastolla U, Fresno M. ACE2 Serum Levels as Predictor of Infectability and Outcome in COVID-19. Front Immunol 2022;13:836516. [DOI: 10.3389/fimmu.2022.836516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Xiang J, Lu M, Shi M, Cheng X, Kwakwa KA, Davis JL, Su X, Bakewell SJ, Zhang Y, Fontana F, Xu Y, Veis DJ, DiPersio JF, Ratner L, Sanderson RD, Noseda A, Mollah S, Li J, Weilbaecher KN. Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19. J Virol 2022;:e0005722. [PMID: 35319225 DOI: 10.1128/jvi.00057-22] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
33 Sadraeian M, Junior FFP, Miranda M, Galinskas J, Fernandes RS, da Cruz EF, Fu L, Zhang L, Diaz RS, Cabral-Miranda G, Guimarães FEG. Study of Viral Photoinactivation by UV-C Light and Photosensitizer Using a Pseudotyped Model. Pharmaceutics 2022;14:683. [PMID: 35336059 DOI: 10.3390/pharmaceutics14030683] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
34 Bowen JE, Sprouse KR, Walls AC, Mazzitelli IG, Logue JK, Franko NM, Ahmed K, Shariq A, Cameroni E, Gori A, Bandera A, Posavad CM, Dan JM, Zhang Z, Weiskopf D, Sette A, Crotty S, Iqbal NT, Corti D, Geffner J, Grifantini R, Chu HY, Veesler D. Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines. bioRxiv 2022:2022. [PMID: 35313570 DOI: 10.1101/2022.03.15.484542] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
35 Cole KH, Bouin A, Ruiz C, Semler BL, Inlay MA, Lupták A. Single-tube collection and nucleic acid analysis of clinical samples for SARS-CoV-2 saliva testing. Sci Rep 2022;12:3951. [PMID: 35273232 DOI: 10.1038/s41598-022-07871-4] [Reference Citation Analysis]
36 Misra A, Theel ES, Humphries RM. Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It? J Clin Microbiol. [DOI: 10.1128/jcm.00482-21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Walls AC, Sprouse KR, Bowen JE, Joshi A, Franko N, Navarro MJ, Stewart C, Cameroni E, McCallum M, Goecker EA, Degli-Angeli EJ, Logue J, Greninger A, Corti D, Chu HY, Veesler D. SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. Cell 2022;185:872-880.e3. [PMID: 35123650 DOI: 10.1016/j.cell.2022.01.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 30.0] [Reference Citation Analysis]
38 Pecora A, Malacari DA, Mozgovoj MV, Díaz MDLÁ, Peralta AV, Cacciabue M, Puebla AF, Carusso C, Mundo SL, Gonzalez Lopez Ledesma MM, Gamarnik AV, Rinaldi O, Vidal O, Mas J, Dus Santos MJ. Anthropogenic Infection of Domestic Cats With SARS-CoV-2 Alpha Variant B.1.1.7 Lineage in Buenos Aires. Front Vet Sci 2022;9:790058. [DOI: 10.3389/fvets.2022.790058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Weinstein JB, Bates TA, Leier HC, McBride SK, Barklis E, Tafesse FG. A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants. iScience 2022;:103960. [PMID: 35224467 DOI: 10.1016/j.isci.2022.103960] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
40 Mittal A, Khattri A, Verma V. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. PLoS Pathog 2022;18:e1010260. [PMID: 35176090 DOI: 10.1371/journal.ppat.1010260] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
41 Muik A, Lui BG, Wallisch AK, Bacher M, Mühl J, Reinholz J, Ozhelvaci O, Beckmann N, Güimil Garcia RC, Poran A, Shpyro S, Finlayson A, Cai H, Yang Q, Swanson KA, Türeci Ö, Şahin U. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science 2022;375:678-80. [PMID: 35040667 DOI: 10.1126/science.abn7591] [Cited by in Crossref: 111] [Cited by in F6Publishing: 88] [Article Influence: 111.0] [Reference Citation Analysis]
42 Ying B, Scheaffer SM, Whitener B, Liang CY, Dmytrenko O, Mackin S, Wu K, Lee D, Avena LE, Chong Z, Case JB, Ma L, Kim T, Sein C, Woods A, Berrueta DM, Carfi A, Elbashir SM, Edwards DK, Thackray LB, Diamond MS. Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice. bioRxiv 2022:2022. [PMID: 35169795 DOI: 10.1101/2022.02.07.479419] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
43 O'Donnell KL, Clancy CS, Griffin AJ, Shifflett K, Gourdine T, Thomas T, Long CM, Furuyama W, Marzi A. Optimization of Single-Dose VSV-Based COVID-19 Vaccination in Hamsters. Front Immunol 2021;12:788235. [PMID: 35069564 DOI: 10.3389/fimmu.2021.788235] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
44 Cao J, Liu Y, Zhou M, Dong S, Hou Y, Jia X, Lan X, Zhang Y, Guo J, Xiao G, Wang W. Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19. Viruses 2022;14:353. [DOI: 10.3390/v14020353] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
45 Ying B, Whitener B, VanBlargan LA, Hassan AO, Shrihari S, Liang CY, Karl CE, Mackin S, Chen RE, Kafai NM, Wilks SH, Smith DJ, Carreño JM, Singh G, Krammer F, Carfi A, Elbashir SM, Edwards DK, Thackray LB, Diamond MS. Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. Sci Transl Med 2022;14:eabm3302. [PMID: 34846168 DOI: 10.1126/scitranslmed.abm3302] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
46 Maciola AK, La Raja M, Pacenti M, Salata C, De Silvestro G, Rosato A, Pasqual G. Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition. Front Immunol 2022;13:830710. [DOI: 10.3389/fimmu.2022.830710] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
47 Chivese T, Matizanadzo JT, Musa OAH, Hindy G, Furuya-kanamori L, Islam N, Al-shebly R, Shalaby R, Habibullah M, Al-marwani TA, Hourani RF, Nawaz AD, Haider MZ, Emara MM, Cyprian F, Doi SAR. The prevalence of adaptive immunity to COVID-19 and reinfection after recovery – a comprehensive systematic review and meta-analysis. Pathogens and Global Health. [DOI: 10.1080/20477724.2022.2029301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Park YJ, De Marco A, Starr TN, Liu Z, Pinto D, Walls AC, Zatta F, Zepeda SK, Bowen JE, Sprouse KR, Joshi A, Giurdanella M, Guarino B, Noack J, Abdelnabi R, Foo SC, Rosen LE, Lempp FA, Benigni F, Snell G, Neyts J, Whelan SPJ, Virgin HW, Bloom JD, Corti D, Pizzuto MS, Veesler D. Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. Science 2022;375:449-54. [PMID: 34990214 DOI: 10.1126/science.abm8143] [Cited by in Crossref: 40] [Cited by in F6Publishing: 23] [Article Influence: 40.0] [Reference Citation Analysis]
49 Van Ert HA, Bohan DW, Rogers K, Fili M, Rojas Chávez RA, Qing E, Han C, Dempewolf S, Hu G, Schwery N, Sevcik K, Ruggio N, Boyt D, Pentella MA, Gallagher T, Jackson JB, Merrill AE, Knudson CM, Brown GD, Maury W, Haim H. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein. Microbiol Spectr 2022;:e0267621. [PMID: 35080430 DOI: 10.1128/spectrum.02676-21] [Reference Citation Analysis]
50 Gonzalez Lopez Ledesma MM, Sanchez L, Ojeda DS, Oviedo Rouco S, Rossi AH, Varese A, Mazzitelli I, Pascuale CA, Miglietta EA, Rodríguez PE, Pallarés HM, Costa Navarro GS, Caramelo JJ, Rothlauf PW, Liu Z, Bloyet LM, Cornejo Pontelli M, Rasetto NB, Wenker SD, Ramis LY, Bialer MG, de Leone MJ, Hernando CE, Bianchimano L, Ríos AS, Treffinger Cienfuegos MS, Rodriguez García DR, Longueira Y, Laufer N, Alvarez D, Ceballos A, Ochoa V, Monzani C, Turk G, Salvatori M, Carradori J, Prost K, Rima A, Varela C, Ercole R, Toro RI, Gutierrez S, Zubieta M, Acuña D, Nabaes Jodar MS, Torres C, Mojsiejczuk L, Viegas M, Velazquez P, Testa C, Kreplak N, Yanovsky M, Whelan S, Geffner J, Pifano M, Gamarnik AV. Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time. mBio 2022;:e0344221. [PMID: 35073758 DOI: 10.1128/mbio.03442-21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
51 Gentles LE, Kehoe L, Crawford KHD, Lacombe K, Dickerson J, Wolf C, Yuan J, Schuler S, Watson JT, Nyanseor S, Briggs-Hagen M, Saydah S, Midgley CM, Pringle K, Chu H, Bloom JD, Englund JA. Dynamics of infection-elicited SARS-CoV-2 antibodies in children over time. medRxiv 2022:2022. [PMID: 35118481 DOI: 10.1101/2022.01.14.22269235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
52 Gilchuk P, Thomsen I, Yoder S, Brady E, Chappell JD, Stevens LJ, Denison MR, Sutton RE, Chen RE, VanBlargan LA, Suryadevara N, Zost SJ, Schmitz J, Pulley JM, Diamond MS, Rhoads JP, Bernard GR, Self WH, Rice TW, Wheeler AP, Crowe JE Jr, Carnahan RH. Standardized two-step testing of antibody activity in COVID-19 convalescent plasma. iScience 2022;25:103602. [PMID: 34901783 DOI: 10.1016/j.isci.2021.103602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
53 VanBlargan LA, Errico JM, Halfmann PJ, Zost SJ, Crowe JE Jr, Purcell LA, Kawaoka Y, Corti D, Fremont DH, Diamond MS. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med 2022. [PMID: 35046573 DOI: 10.1038/s41591-021-01678-y] [Cited by in Crossref: 221] [Cited by in F6Publishing: 135] [Article Influence: 221.0] [Reference Citation Analysis]
54 Son J, Huang S, Zeng Q, Bricker TL, Case JB, Zhou J, Zang R, Liu Z, Chang X, Darling TL, Xu J, Harastani HH, Chen L, Gomez Castro MF, Zhao Y, Kohio HP, Hou G, Fan B, Niu B, Guo R, Rothlauf PW, Bailey AL, Wang X, Shi PY, Martinez ED, Brody SL, Whelan SPJ, Diamond MS, Boon ACM, Li B, Ding S. JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis. mBio 2022;:e0337721. [PMID: 35038906 DOI: 10.1128/mbio.03377-21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
55 Borgogna C, Bruna R, Griffante G, Martuscelli L, De Andrea M, Ferrante D, Patriarca A, Mahmoud AM, Gaidano V, Marchetti M, Rapezzi D, Lai M, Pistello M, Ladetto M, Massaia M, Gaidano G, Gariglio M. Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients. Blood Cancer J 2022;12. [DOI: 10.1038/s41408-022-00608-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Septisetyani EP, Prasetyaningrum PW, Anam K, Santoso A. SARS-CoV-2 Antibody Neutralization Assay Platforms Based on Epitopes Sources: Live Virus, Pseudovirus, and Recombinant S Glycoprotein RBD. Immune Netw 2021;21:e39. [PMID: 35036026 DOI: 10.4110/in.2021.21.e39] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Li N, Chen XL, Li Q, Zhang ZR, Deng CL, Zhang B, Li XD, Ye HQ. A new screening system for entry inhibitors based on cell-to-cell transmitted syncytia formation mediated by self-propagating hybrid VEEV-SARS-CoV-2 replicon. Emerg Microbes Infect 2022;:1-28. [PMID: 35034586 DOI: 10.1080/22221751.2022.2030198] [Reference Citation Analysis]
58 Salazar-garcía M, Acosta-contreras S, Rodríguez-martínez G, Cruz-rangel A, Flores-alanis A, Patiño-lópez G, Luna-pineda VM. Pseudotyped Vesicular Stomatitis Virus-Severe Acute Respiratory Syndrome-Coronavirus-2 Spike for the Study of Variants, Vaccines, and Therapeutics Against Coronavirus Disease 2019. Front Microbiol 2022;12:817200. [DOI: 10.3389/fmicb.2021.817200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
59 Park SB, Irvin P, Hu Z, Khan M, Hu X, Zeng Q, Chen C, Xu M, Leek M, Zang R, Case JB, Zheng W, Ding S, Liang TJ. Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors. mBio 2022;:e0323821. [PMID: 35012356 DOI: 10.1128/mbio.03238-21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
60 Furuyama W, Shifflett K, Pinski AN, Griffin AJ, Feldmann F, Okumura A, Gourdine T, Jankeel A, Lovaglio J, Hanley PW, Thomas T, Clancy CS, Messaoudi I, O'Donnell KL, Marzi A. Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine. mBio 2022;:e0337921. [PMID: 35012339 DOI: 10.1128/mbio.03379-21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
61 Zeng C, Evans JP, King T, Zheng YM, Oltz EM, Whelan SPJ, Saif LJ, Peeples ME, Liu SL. SARS-CoV-2 spreads through cell-to-cell transmission. Proc Natl Acad Sci U S A 2022;119:e2111400119. [PMID: 34937699 DOI: 10.1073/pnas.2111400119] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
62 Brown JA, Sanidad KZ, Lucotti S, Lieber CM, Cox RM, Ananthanarayanan A, Basu S, Chen J, Shan M, Amir M, Schmidt F, Weisblum Y, Cioffi M, Li T, Rowdo FM, Martin ML, Guo CJ, Lyssiotis C, Layden BT, Dannenberg AJ, Bieniasz PD, Lee B, Inohara N, Matei I, Plemper RK, Zeng MY. Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection. Gut Microbes 2022;14:2105609. [PMID: 35915556 DOI: 10.1080/19490976.2022.2105609] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 VanBlargan L, Errico J, Halfmann P, Zost S, Crowe J, Purcell L, Kawaoka Y, Corti D, Fremont D, Diamond M. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Res Sq 2021:rs. [PMID: 34981042 DOI: 10.21203/rs.3.rs-1175516/v1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 34.0] [Reference Citation Analysis]
64 Banga Ndzouboukou JL, Zhang YD, Fan XL. Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods. Curr Med Sci 2021;41:1052-64. [PMID: 34935114 DOI: 10.1007/s11596-021-2470-7] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
65 White JM, Schiffer JT, Bender Ignacio RA, Xu S, Kainov D, Ianevski A, Aittokallio T, Frieman M, Olinger GG, Polyak SJ, Prasad VR. Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. mBio 2021;12:e03347-21. [DOI: 10.1128/mbio.03347-21] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
66 Bowen JE, Walls AC, Joshi A, Sprouse KR, Stewart C, Tortorici MA, Franko NM, Logue JK, Mazzitelli IG, Tiles SW, Ahmed K, Shariq A, Snell G, Iqbal NT, Geffner J, Bandera A, Gori A, Grifantini R, Chu HY, Van Voorhis WC, Corti D, Veesler D. SARS-CoV-2 spike conformation determines plasma neutralizing activity. bioRxiv 2021:2021. [PMID: 34981060 DOI: 10.1101/2021.12.19.473391] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
67 Goldblatt D, Fiore-Gartland A, Johnson M, Hunt A, Bengt C, Zavadska D, Snipe HD, Brown JS, Workman L, Zar HJ, Montefiori D, Shen X, Dull P, Plotkin S, Siber G, Ambrosino D. Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine 2021:S0264-410X(21)01615-7. [PMID: 34933765 DOI: 10.1016/j.vaccine.2021.12.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 33.0] [Reference Citation Analysis]
68 Wang Y, Tang CY, Wan XF. Antigenic characterization of influenza and SARS-CoV-2 viruses. Anal Bioanal Chem 2021. [PMID: 34905077 DOI: 10.1007/s00216-021-03806-6] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
69 Walls AC, Sprouse KR, Joshi A, Bowen JE, Franko N, Navarro MJ, Stewart C, McCallum M, Goecker EA, Degli-Angeli EJ, Logue J, Greninger A, Chu H, Veesler D. Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responses. bioRxiv 2021:2021. [PMID: 34931192 DOI: 10.1101/2021.12.08.471707] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
70 Wu Y, Wang M, Yin H, Ming S, Li X, Jiang G, Liu Y, Wang P, Zhou G, Liu L, Gong S, Zhou H, Shan H, Huang X. TREM-2 is a sensor and activator of T cell response in SARS-CoV-2 infection. Sci Adv 2021;7:eabi6802. [PMID: 34878838 DOI: 10.1126/sciadv.abi6802] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
71 Joyce MG, Chen W, Sankhala RS, Hajduczki A, Thomas PV, Choe M, Martinez EJ, Chang WC, Peterson CE, Morrison EB, Smith C, Chen RE, Ahmed A, Wieczorek L, Anderson A, Case JB, Li Y, Oertel T, Rosado L, Ganesh A, Whalen C, Carmen JM, Mendez-rivera L, Karch CP, Gohain N, Villar Z, Mccurdy D, Beck Z, Kim J, Shrivastava S, Jobe O, Dussupt V, Molnar S, Tran U, Kannadka CB, Soman S, Kuklis C, Zemil M, Khanh H, Wu W, Cole MA, Duso DK, Kummer LW, Lang TJ, Muncil SE, Currier JR, Krebs SJ, Polonis VR, Rajan S, Mctamney PM, Esser MT, Reiley WW, Rolland M, de Val N, Diamond MS, Gromowski GD, Matyas GR, Rao M, Michael NL, Modjarrad K. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell Reports 2021;37:110143. [DOI: 10.1016/j.celrep.2021.110143] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
72 Chmielewska AM, Czarnota A, Bieńkowska-Szewczyk K, Grzyb K. Immune response against SARS-CoV-2 variants: the role of neutralization assays. NPJ Vaccines 2021;6:142. [PMID: 34845231 DOI: 10.1038/s41541-021-00404-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
73 Morales-Núñez JJ, Muñoz-Valle JF, Torres-Hernández PC, Hernández-Bello J. Overview of Neutralizing Antibodies and Their Potential in COVID-19. Vaccines (Basel) 2021;9:1376. [PMID: 34960121 DOI: 10.3390/vaccines9121376] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
74 Bohan D, Van Ert H, Ruggio N, Rogers KJ, Badreddine M, Aguilar Briseño JA, Elliff JM, Rojas Chavez RA, Gao B, Stokowy T, Christakou E, Kursula P, Micklem D, Gausdal G, Haim H, Minna J, Lorens JB, Maury W. Phosphatidylserine receptors enhance SARS-CoV-2 infection. PLoS Pathog 2021;17:e1009743. [PMID: 34797899 DOI: 10.1371/journal.ppat.1009743] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
75 Griffante G, Chandel S, Ferrante D, Caneparo V, Capello D, Bettio V, Borgogna C, Aleni C, Esposito S, Sarro A, Vasile A, Comba M, Testa T, Cotrupi G, De Andrea M, Bortoluzzi S, Gariglio M. Persistence of Neutralizing Antibodies to SARS-CoV-2 in First Wave Infected Individuals at Ten Months Post-Infection: The UnIRSA Cohort Study. Viruses 2021;13:2270. [PMID: 34835076 DOI: 10.3390/v13112270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
76 Feng F, Chen J, Zhao J, Li Y, Li M, Sun C. Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection. Viruses 2021;13:2243. [PMID: 34835049 DOI: 10.3390/v13112243] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
77 Lai CY, To A, Ann S Wong T, Lieberman MM, Clements DE, Senda JT, Ball AH, Pessaint L, Andersen H, Furuyama W, Marzi A, Donini O, Lehrer AT. Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice. Vaccine X 2021;:100126. [PMID: 34778744 DOI: 10.1016/j.jvacx.2021.100126] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
78 Pishesha N, Harmand TJ, Rothlauf PW, Praest P, Alexander RK, van den Doel R, Liebeskind MJ, Vakaki MA, McCaul N, Wijne C, Verhaar E, Pinney W 3rd, Heston H, Bloyet LM, Pontelli MC, Ilagan MXG, Jan Lebbink R, Buchser WJ, Wiertz EJHJ, Whelan SPJ, Ploegh HL. A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants. Proc Natl Acad Sci U S A 2021;118:e2116147118. [PMID: 34654739 DOI: 10.1073/pnas.2116147118] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
79 Wohlgemuth N, Whitt K, Cherry S, Kirkpatrick Roubidoux E, Lin CY, Allison KJ, Gowen A, Freiden P, Allen EK, Gaur AH, Estepp JH, Tang L, Mori T, Hijano DR, Hakim H, McGargill MA, Krammer F, Whitt MA, Wolf J, Thomas PG, Schultz-Cherry S; St. Jude Investigative Team,. An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization. Microbiol Spectr 2021;9:e0105921. [PMID: 34704832 DOI: 10.1128/Spectrum.01059-21] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
80 Chen HY, Huang C, Tian L, Huang X, Zhang C, Llewellyn GN, Rogers GL, Andresen K, O'Gorman MRG, Chen YW, Cannon PM. Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation. J Virol 2021;95:e0096621. [PMID: 34495700 DOI: 10.1128/JVI.00966-21] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
81 Mahoney M, Damalanka VC, Tartell MA, Chung DH, Lourenço AL, Pwee D, Mayer Bridwell AE, Hoffmann M, Voss J, Karmakar P, Azouz NP, Klingler AM, Rothlauf PW, Thompson CE, Lee M, Klampfer L, Stallings CL, Rothenberg ME, Pöhlmann S, Whelan SPJ, O'Donoghue AJ, Craik CS, Janetka JW. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. Proc Natl Acad Sci U S A 2021;118:e2108728118. [PMID: 34635581 DOI: 10.1073/pnas.2108728118] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
82 Su W, Sia SF, Schmitz AJ, Bricker TL, Starr TN, Greaney AJ, Turner JS, Mohammed BM, Liu Z, Choy KT, Darling TL, Joshi A, Cheng KM, Wong AYL, Harastani HH, Nicholls JM, Whelan SPJ, Bloom JD, Yen HL, Ellebedy AH, Boon ACM. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters. mBio 2021;12:e0239521. [PMID: 34517754 DOI: 10.1128/mBio.02395-21] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
83 Errico JM, Zhao H, Chen RE, Liu Z, Case JB, Ma M, Schmitz AJ, Rau MJ, Fitzpatrick JAJ, Shi PY, Diamond MS, Whelan SPJ, Ellebedy AH, Fremont DH. Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD. Cell Rep 2021;37:109881. [PMID: 34655519 DOI: 10.1016/j.celrep.2021.109881] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
84 Marchand A, Roulland I, Semence F, Beck O, Ericsson M. Use of Quantitative Dried Blood Spots to Evaluate the Post-Vaccination Level of Neutralizing Antibodies against SARS-CoV-2. Life (Basel) 2021;11:1125. [PMID: 34833001 DOI: 10.3390/life11111125] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Boulton S, Poutou J, Martin NT, Azad T, Singaravelu R, Crupi MJF, Jamieson T, He X, Marius R, Petryk J, Tanese de Souza C, Austin B, Taha Z, Whelan J, Khan ST, Pelin A, Rezaei R, Surendran A, Tucker S, Brown EEF, Dave J, Diallo JS, Auer R, Angel JB, Cameron DW, Cailhier JF, Lapointe R, Potts K, Mahoney DJ, Bell JC, Ilkow CS. Single-dose replicating poxvirus vector-basedRBD vaccine drives robust humoral and T cellimmune response against SARS-CoV-2 infection. Mol Ther 2021:S1525-0016(21)00515-3. [PMID: 34687845 DOI: 10.1016/j.ymthe.2021.10.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
86 Kreutzberger AJB, Sanyal A, Ojha R, Pyle JD, Vapalahti O, Balistreri G, Kirchhausen T. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease. J Virol 2021;95:e0097521. [PMID: 34406858 DOI: 10.1128/JVI.00975-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
87 Lerer E, Oren Z, Kafri Y, Adar Y, Toister E, Cherry L, Lupu E, Monash A, Levy R, Dor E, Epstein E, Levin L, Girshengorn M, Natan N, Zichel R, Makovitzki A. Highly Efficient Purification of Recombinant VSV-∆G-Spike Vaccine against SARS-CoV-2 by Flow-Through Chromatography. BioTech 2021;10:22. [DOI: 10.3390/biotech10040022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
88 Kramer KJ, Johnson NV, Shiakolas AR, Suryadevara N, Periasamy S, Raju N, Williams JK, Wrapp D, Zost SJ, Walker LM, Wall SC, Holt CM, Hsieh CL, Sutton RE, Paulo A, Nargi RS, Davidson E, Doranz BJ, Crowe JE Jr, Bukreyev A, Carnahan RH, McLellan JS, Georgiev IS. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. Cell Rep 2021;37:109784. [PMID: 34592170 DOI: 10.1016/j.celrep.2021.109784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
89 Wang S, Li L, Yan F, Gao Y, Yang S, Xia X. COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects. Vaccines (Basel) 2021;9:1082. [PMID: 34696190 DOI: 10.3390/vaccines9101082] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
90 Mishra N, Kumar S, Singh S, Bansal T, Jain N, Saluja S, Kumar R, Bhattacharyya S, Palanichamy JK, Mir RA, Sinha S, Luthra K. Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma. PLoS Pathog 2021;17:e1009958. [PMID: 34559854 DOI: 10.1371/journal.ppat.1009958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
91 Dong J, Zost SJ, Greaney AJ, Starr TN, Dingens AS, Chen EC, Chen RE, Case JB, Sutton RE, Gilchuk P, Rodriguez J, Armstrong E, Gainza C, Nargi RS, Binshtein E, Xie X, Zhang X, Shi PY, Logue J, Weston S, McGrath ME, Frieman MB, Brady T, Tuffy KM, Bright H, Loo YM, McTamney PM, Esser MT, Carnahan RH, Diamond MS, Bloom JD, Crowe JE Jr. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nat Microbiol 2021;6:1233-44. [PMID: 34548634 DOI: 10.1038/s41564-021-00972-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 65] [Article Influence: 5.0] [Reference Citation Analysis]
92 King HAD, Joyce MG, Lakhal-Naouar I, Ahmed A, Cincotta CM, Subra C, Peachman KK, Hack HR, Chen RE, Thomas PV, Chen WH, Sankhala RS, Hajduczki A, Martinez EJ, Peterson CE, Chang WC, Choe M, Smith C, Headley JA, Elyard HA, Cook A, Anderson A, Wuertz KM, Dong M, Swafford I, Case JB, Currier JR, Lal KG, Amare MF, Dussupt V, Molnar S, Daye SP, Zeng X, Barkei EK, Alfson K, Staples HM, Carrion R, Krebs SJ, Paquin-Proulx D, Karasavvas N, Polonis VR, Jagodzinski LL, Vasan S, Scott PT, Huang Y, Nair MS, Ho DD, de Val N, Diamond MS, Lewis MG, Rao M, Matyas GR, Gromowski GD, Peel SA, Michael NL, Modjarrad K, Bolton DL. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. Proc Natl Acad Sci U S A 2021;118:e2106433118. [PMID: 34470866 DOI: 10.1073/pnas.2106433118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
93 Schmitz AJ, Turner JS, Liu Z, Zhou JQ, Aziati ID, Chen RE, Joshi A, Bricker TL, Darling TL, Adelsberg DC, Altomare CG, Alsoussi WB, Case JB, VanBlargan LA, Lei T, Thapa M, Amanat F, Jeevan T, Fabrizio T, O'Halloran JA, Shi PY, Presti RM, Webby RJ, Krammer F, Whelan SPJ, Bajic G, Diamond MS, Boon ACM, Ellebedy AH. A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. Immunity 2021;54:2159-2166.e6. [PMID: 34464596 DOI: 10.1016/j.immuni.2021.08.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
94 Priyadarsini AJ, Karan K, Arulselvi S. The Convalescent Plasma Craze! Where Does India Stand? J Lab Physicians 2021;13:183-91. [PMID: 34483567 DOI: 10.1055/s-0041-1730753] [Reference Citation Analysis]
95 Oâ Donnell KL, Clancy CS, Griffin AJ, Shifflett K, Gourdine T, Thomas T, Long CM, Furuyama W, Marzi A. Optimization of single dose VSV-based COVID-19 vaccination in hamsters. bioRxiv 2021:2021. [PMID: 34518839 DOI: 10.1101/2021.09.03.458735] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Ying B, Whitener B, VanBlargan LA, Hassan AO, Shrihari S, Liang CY, Karl CE, Mackin S, Chen RE, Kafai NM, Wilks SH, Smith DJ, Carreño JM, Singh G, Krammer F, Carfi A, Elbashir S, Edwards DK, Thackray LB, Diamond MS. Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. bioRxiv 2021:2021. [PMID: 34462745 DOI: 10.1101/2021.08.25.457693] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
97 Chen EC, Gilchuk P, Zost SJ, Suryadevara N, Winkler ES, Cabel CR, Binshtein E, Chen RE, Sutton RE, Rodriguez J, Day S, Myers L, Trivette A, Williams JK, Davidson E, Li S, Doranz BJ, Campos SK, Carnahan RH, Thorne CA, Diamond MS, Crowe JE Jr. Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. Cell Rep 2021;36:109604. [PMID: 34411541 DOI: 10.1016/j.celrep.2021.109604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
98 Stefan MA, Light YK, Schwedler JL, McIlroy PR, Courtney CM, Saada EA, Thatcher CE, Phillips AM, Bourguet FA, Mageeney CM, McCloy SA, Collette NM, Negrete OA, Schoeniger JS, Weilhammer DR, Harmon B. Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies. MAbs 2021;13:1958663. [PMID: 34348076 DOI: 10.1080/19420862.2021.1958663] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
99 Hu X, Chen CZ, Xu M, Hu Z, Guo H, Itkin Z, Shinn P, Ivin P, Leek M, Liang TJ, Shen M, Zheng W, Hall MD. Discovery of Small Molecule Entry Inhibitors Targeting the Fusion Peptide of SARS-CoV-2 Spike Protein. ACS Med Chem Lett 2021;12:1267-74. [PMID: 34394844 DOI: 10.1021/acsmedchemlett.1c00263] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
100 Kreutzberger AJB, Sanyal A, Ojha R, Pyle JD, Vapalahti O, Balistreri G, Kirchhausen T. Synergistic block of SARS-CoV-2 infection by combined drug inhibition of the host entry factors PIKfyve kinase and TMPRSS2 protease. bioRxiv 2021:2021. [PMID: 34100014 DOI: 10.1101/2021.06.01.446623] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Pinto D, Sauer MM, Czudnochowski N, Low JS, Tortorici MA, Housley MP, Noack J, Walls AC, Bowen JE, Guarino B, Rosen LE, di Iulio J, Jerak J, Kaiser H, Islam S, Jaconi S, Sprugasci N, Culap K, Abdelnabi R, Foo C, Coelmont L, Bartha I, Bianchi S, Silacci-Fregni C, Bassi J, Marzi R, Vetti E, Cassotta A, Ceschi A, Ferrari P, Cippà PE, Giannini O, Ceruti S, Garzoni C, Riva A, Benigni F, Cameroni E, Piccoli L, Pizzuto MS, Smithey M, Hong D, Telenti A, Lempp FA, Neyts J, Havenar-Daughton C, Lanzavecchia A, Sallusto F, Snell G, Virgin HW, Beltramello M, Corti D, Veesler D. Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science 2021:eabj3321. [PMID: 34344823 DOI: 10.1126/science.abj3321] [Cited by in Crossref: 3] [Cited by in F6Publishing: 72] [Article Influence: 3.0] [Reference Citation Analysis]
102 Miersch S, Li Z, Saberianfar R, Ustav M, Brett Case J, Blazer L, Chen C, Ye W, Pavlenco A, Gorelik M, Garcia Perez J, Subramania S, Singh S, Ploder L, Ganaie S, Chen RE, Leung DW, Pandolfi PP, Novelli G, Matusali G, Colavita F, Capobianchi MR, Jain S, Gupta JB, Amarasinghe GK, Diamond MS, Rini J, Sidhu SS. Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations. J Mol Biol 2021;433:167177. [PMID: 34329642 DOI: 10.1016/j.jmb.2021.167177] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
103 Stelitano D, Weisberg SP, Goldklang MP, Zhu Y, Bovier FT, Kalantarov GF, Greco G, Decimo D, Franci G, Cennamo M, Portella G, Galdiero M, Mathieu C, Horvat B, Trakht IN, Moscona A, Whitt MA, Porotto M. Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals. mSphere 2021;6:e0057121. [PMID: 34319126 DOI: 10.1128/mSphere.00571-21] [Reference Citation Analysis]
104 Kramer KJ, Wilfong EM, Voss K, Barone SM, Shiakolas AR, Raju N, Roe CE, Suryadevara N, Walker L, Wall SC, Paulo A, Schaefer S, Dahunsi D, Westlake CS, Crowe JE, Carnahan RH, Rathmell JC, Bonami RH, Georgiev IS, Irish JM. Single-Cell Profiling of the Antigen-Specific Response to BNT162b2 SARS-CoV-2 RNA Vaccine. bioRxiv 2021:2021. [PMID: 34341788 DOI: 10.1101/2021.07.28.453981] [Reference Citation Analysis]
105 Ikegame S, Siddiquey MNA, Hung CT, Haas G, Brambilla L, Oguntuyo KY, Kowdle S, Chiu HP, Stevens CS, Vilardo AE, Edelstein A, Perandones C, Kamil JP, Lee B. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Nat Commun 2021;12:4598. [PMID: 34312390 DOI: 10.1038/s41467-021-24909-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
106 Bayarri-Olmos R, Idorn M, Rosbjerg A, Pérez-Alós L, Hansen CB, Johnsen LB, Helgstrand C, Zosel F, Bjelke JR, Öberg FK, Søgaard M, Paludan SR, Bak-Thomsen T, Jardine JG, Skjoedt MO, Garred P. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain. J Immunol 2021;207:878-87. [PMID: 34301847 DOI: 10.4049/jimmunol.2100272] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
107 Noori M, Nejadghaderi SA, Arshi S, Carson-Chahhoud K, Ansarin K, Kolahi AA, Safiri S. Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies. Rev Med Virol 2021;:e2277. [PMID: 34286893 DOI: 10.1002/rmv.2277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
108 Borgogna C, De Andrea M, Griffante G, Lai A, Bergna A, Galli M, Zehender G, Castello L, Ravanini P, Cattrini C, Mennitto A, Gennari A, Gariglio M. SARS-CoV-2 reinfection in a cancer patient with a defective neutralizing humoral response. J Med Virol 2021. [PMID: 34260066 DOI: 10.1002/jmv.27200] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
109 Starr TN, Czudnochowski N, Liu Z, Zatta F, Park YJ, Addetia A, Pinto D, Beltramello M, Hernandez P, Greaney AJ, Marzi R, Glass WG, Zhang I, Dingens AS, Bowen JE, Tortorici MA, Walls AC, Wojcechowskyj JA, De Marco A, Rosen LE, Zhou J, Montiel-Ruiz M, Kaiser H, Dillen JR, Tucker H, Bassi J, Silacci-Fregni C, Housley MP, di Iulio J, Lombardo G, Agostini M, Sprugasci N, Culap K, Jaconi S, Meury M, Dellota E Jr, Abdelnabi R, Foo SC, Cameroni E, Stumpf S, Croll TI, Nix JC, Havenar-Daughton C, Piccoli L, Benigni F, Neyts J, Telenti A, Lempp FA, Pizzuto MS, Chodera JD, Hebner CM, Virgin HW, Whelan SPJ, Veesler D, Corti D, Bloom JD, Snell G. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature 2021;597:97-102. [PMID: 34261126 DOI: 10.1038/s41586-021-03807-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 99] [Article Influence: 9.0] [Reference Citation Analysis]
110 Hassan AO, Shrihari S, Gorman MJ, Ying B, Yaun D, Raju S, Chen RE, Dmitriev IP, Kashentseva E, Adams LJ, Mann C, Davis-Gardner ME, Suthar MS, Shi PY, Saphire EO, Fremont DH, Curiel DT, Alter G, Diamond MS. An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. Cell Rep 2021;36:109452. [PMID: 34289385 DOI: 10.1016/j.celrep.2021.109452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
111 Lau EY, Negrete OA, Bennett WFD, Bennion BJ, Borucki M, Bourguet F, Epstein A, Franco M, Harmon B, He S, Jones D, Kim H, Kirshner D, Lao V, Lo J, McLoughlin K, Mosesso R, Murugesh DK, Saada EA, Segelke B, Stefan MA, Stevenson GA, Torres MW, Weilhammer DR, Wong S, Yang Y, Zemla A, Zhang X, Zhu F, Allen JE, Lightstone FC. Discovery of Small-Molecule Inhibitors of SARS-CoV-2 Proteins Using a Computational and Experimental Pipeline. Front Mol Biosci 2021;8:678701. [PMID: 34327214 DOI: 10.3389/fmolb.2021.678701] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
112 Rossi AH, Ojeda DS, Varese A, Sanchez L, Gonzalez Lopez Ledesma MM, Mazzitelli I, Alvarez Juliá A, Oviedo Rouco S, Pallarés HM, Costa Navarro GS, Rasetto NB, Garcia CI, Wenker SD, Ramis LY, Bialer MG, de Leone MJ, Hernando CE, Sosa S, Bianchimano L, Rios AS, Treffinger Cienfuegos MS, Caramelo JJ, Longueira Y, Laufer N, Alvarez DE, Carradori J, Pedrozza D, Rima A, Echegoyen C, Ercole R, Gelpi P, Marchetti S, Zubieta M, Docena G, Kreplak N, Yanovsky M, Geffner J, Pifano M, Gamarnik AV. Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose. Cell Rep Med 2021;2:100359. [PMID: 34308389 DOI: 10.1016/j.xcrm.2021.100359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
113 Hunt AC, Case JB, Park YJ, Cao L, Wu K, Walls AC, Liu Z, Bowen JE, Yeh HW, Saini S, Helms L, Zhao YT, Hsiang TY, Starr TN, Goreshnik I, Kozodoy L, Carter L, Ravichandran R, Green LB, Matochko WL, Thomson CA, Vögeli B, Krüger-Gericke A, VanBlargan LA, Chen RE, Ying B, Bailey AL, Kafai NM, Boyken S, Ljubetič A, Edman N, Ueda G, Chow C, Addetia A, Panpradist N, Gale M, Freedman BS, Lutz BR, Bloom JD, Ruohola-Baker H, Whelan SPJ, Stewart L, Diamond MS, Veesler D, Jewett MC, Baker D. Multivalent designed proteins protect against SARS-CoV-2 variants of concern. bioRxiv 2021:2021. [PMID: 34268509 DOI: 10.1101/2021.07.07.451375] [Reference Citation Analysis]
114 Liu Z, Wu H, Egland KA, Gilliland TC, Dunn MD, Luke TC, Sullivan EJ, Klimstra WB, Bausch CL, Whelan SPJ. Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants. Hum Vaccin Immunother 2021;:1-10. [PMID: 34228597 DOI: 10.1080/21645515.2021.1940652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
115 Rocheleau L, Laroche G, Fu K, Stewart CM, Mohamud AO, Côté M, Giguère PM, Langlois MA, Pelchat M. Identification of a High-Frequency Intrahost SARS-CoV-2 Spike Variant with Enhanced Cytopathic and Fusogenic Effects. mBio 2021;12:e0078821. [PMID: 34182784 DOI: 10.1128/mBio.00788-21] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
116 Turner JS, O'Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, Lei T, Thapa M, Chen RE, Case JB, Amanat F, Rauseo AM, Haile A, Xie X, Klebert MK, Suessen T, Middleton WD, Shi PY, Krammer F, Teefey SA, Diamond MS, Presti RM, Ellebedy AH. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 2021;596:109-13. [PMID: 34182569 DOI: 10.1038/s41586-021-03738-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 205] [Article Influence: 25.0] [Reference Citation Analysis]
117 Bohan D, Ert HV, Ruggio N, Rogers KJ, Badreddine M, Aguilar Briseño JA, Rojas Chavez RA, Gao B, Stokowy T, Christakou E, Micklem D, Gausdal G, Haim H, Minna J, Lorens JB, Maury W. Phosphatidylserine Receptors Enhance SARS-CoV-2 Infection: AXL as a Therapeutic Target for COVID-19. bioRxiv 2021:2021. [PMID: 34159331 DOI: 10.1101/2021.06.15.448419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
118 Puray-Chavez M, LaPak KM, Schrank TP, Elliott JL, Bhatt DP, Agajanian MJ, Jasuja R, Lawson DQ, Davis K, Rothlauf PW, Liu Z, Jo H, Lee N, Tenneti K, Eschbach JE, Shema Mugisha C, Cousins EM, Cloer EW, Vuong HR, VanBlargan LA, Bailey AL, Gilchuk P, Crowe JE Jr, Diamond MS, Hayes DN, Whelan SPJ, Horani A, Brody SL, Goldfarb D, Major MB, Kutluay SB. Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell. Cell Rep 2021;36:109364. [PMID: 34214467 DOI: 10.1016/j.celrep.2021.109364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
119 Najafi Fard S, Petrone L, Petruccioli E, Alonzi T, Matusali G, Colavita F, Castilletti C, Capobianchi MR, Goletti D. In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses. Biomed Res Int 2021;2021:8856018. [PMID: 34239932 DOI: 10.1155/2021/8856018] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
120 Lu Y, Wang J, Li Q, Hu H, Lu J, Chen Z. Advances in Neutralization Assays for SARS‐CoV‐2. Scand J Immunol 2021;94. [DOI: 10.1111/sji.13088] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
121 Meng B, Kemp SA, Papa G, Datir R, Ferreira IATM, Marelli S, Harvey WT, Lytras S, Mohamed A, Gallo G, Thakur N, Collier DA, Mlcochova P, Duncan LM, Carabelli AM, Kenyon JC, Lever AM, De Marco A, Saliba C, Culap K, Cameroni E, Matheson NJ, Piccoli L, Corti D, James LC, Robertson DL, Bailey D, Gupta RK; COVID-19 Genomics UK (COG-UK) Consortium. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Rep 2021;35:109292. [PMID: 34166617 DOI: 10.1016/j.celrep.2021.109292] [Cited by in Crossref: 15] [Cited by in F6Publishing: 143] [Article Influence: 15.0] [Reference Citation Analysis]
122 Son J, Huang S, Zeng Q, Bricker TL, Case JB, Zhou J, Zang R, Liu Z, Chang X, Harastani HH, Chen L, Castro MFG, Zhao Y, Kohio HP, Hou G, Fan B, Niu B, Guo R, Rothlauf PW, Bailey AL, Wang X, Shi PY, Martinez ED, Whelan SPJ, Diamond MS, Boon ACM, Li B, Ding S. JIB-04 has broad-spectrum antiviral activity and inhibits SARS-CoV-2 replication and coronavirus pathogenesis. bioRxiv 2021:2020. [PMID: 32995798 DOI: 10.1101/2020.09.24.312165] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
123 Vandergaast R, Carey T, Reiter S, Lathrum C, Lech P, Gnanadurai C, Haselton M, Buehler J, Narjari R, Schnebeck L, Roesler A, Sevola K, Suksanpaisan L, Bexon A, Naik S, Brunton B, Weaver SC, Rafael G, Tran S, Baum A, Kyratsous CA, Peng KW, Russell SJ. IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers. mSphere 2021;6:e0017021. [PMID: 34077262 DOI: 10.1128/mSphere.00170-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
124 Zeng C, Evans JP, King T, Zheng YM, Oltz EM, Whelan SPJ, Saif L, Peeples ME, Liu SL. SARS-CoV-2 Spreads through Cell-to-Cell Transmission. bioRxiv 2021:2021. [PMID: 34100011 DOI: 10.1101/2021.06.01.446579] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
125 Ikegame S, Siddiquey MNA, Hung CT, Haas G, Brambilla L, Oguntuyo KY, Kowdle S, Vilardo AE, Edelstein A, Perandones C, Kamil JP, Lee B. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. medRxiv 2021:2021. [PMID: 33821288 DOI: 10.1101/2021.03.31.21254660] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
126 Elia U, Rotem S, Bar-Haim E, Ramishetti S, Naidu GS, Gur D, Aftalion M, Israeli M, Bercovich-Kinori A, Alcalay R, Makdasi E, Chitlaru T, Rosenfeld R, Israely T, Melamed S, Abutbul Ionita I, Danino D, Peer D, Cohen O. Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection. Nano Lett 2021;21:4774-9. [PMID: 34032435 DOI: 10.1021/acs.nanolett.1c01284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
127 Joyce MG, Chen WH, Sankhala RS, Hajduczki A, Thomas PV, Choe M, Chang W, Peterson CE, Martinez E, Morrison EB, Smith C, Ahmed A, Wieczorek L, Anderson A, Chen RE, Case JB, Li Y, Oertel T, Rosado L, Ganesh A, Whalen C, Carmen JM, Mendez-Rivera L, Karch C, Gohain N, Villar Z, McCurdy D, Beck Z, Kim J, Shrivastava S, Jobe O, Dussupt V, Molnar S, Tran U, Kannadka CB, Zemil M, Khanh H, Wu W, Cole MA, Duso DK, Kummer LW, Lang TJ, Muncil SE, Currier JR, Krebs SJ, Polonis VR, Rajan S, McTamney PM, Esser MT, Reiley WW, Rolland M, de Val N, Diamond MS, Gromowski GD, Matyas GR, Rao M, Michael NL, Modjarrad K. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. bioRxiv 2021:2021. [PMID: 34013273 DOI: 10.1101/2021.05.09.443331] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 12.0] [Reference Citation Analysis]
128 Harbour JC, Lyski ZL, Schell JB, Thomas A, Messer WB, Slifka MK, Nolz JC. Cellular and Humoral Immune Responses in Mice Immunized with Vaccinia Virus Expressing the SARS-CoV-2 Spike Protein. J Immunol 2021;206:2596-604. [PMID: 33972374 DOI: 10.4049/jimmunol.2100054] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
129 Mahoney M, Damalanka VC, Tartell MA, Chung DH, Lourenco AL, Pwee D, Mayer Bridwell AE, Hoffmann M, Voss J, Karmakar P, Azouz N, Klingler AM, Rothlauf PW, Thompson CE, Lee M, Klampfer L, Stallings C, Rothenberg ME, Pöhlmann S, Whelan SP, O'Donoghue AJ, Craik CS, Janetka JW. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. bioRxiv 2021:2021. [PMID: 34131661 DOI: 10.1101/2021.05.06.442935] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Baldo A, Leunda A, Willemarck N, Pauwels K. Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2. Vaccines (Basel) 2021;9:453. [PMID: 34063733 DOI: 10.3390/vaccines9050453] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
131 Chen EC, Gilchuk P, Zost SJ, Suryadevara N, Winkler ES, Cabel CR, Binshtein E, Sutton RE, Rodriguez J, Day S, Myers L, Trivette A, Williams JK, Davidson E, Li S, Doranz BJ, Campos SK, Carnahan RH, Thorne CA, Diamond MS, Crowe JE. Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. bioRxiv 2021:2021. [PMID: 33972937 DOI: 10.1101/2021.05.02.442326] [Reference Citation Analysis]
132 Shi AC, Ren P. SARS-CoV-2 serology testing: Progress and challenges. J Immunol Methods 2021;494:113060. [PMID: 33915155 DOI: 10.1016/j.jim.2021.113060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
133 Hennrich AA, Sawatsky B, Santos-Mandujano R, Banda DH, Oberhuber M, Schopf A, Pfaffinger V, Wittwer K, Riedel C, Pfaller CK, Conzelmann KK. Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization. PLoS Pathog 2021;17:e1009064. [PMID: 33882114 DOI: 10.1371/journal.ppat.1009064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
134 Perez-Miller S, Patek M, Moutal A, Duran P, Cabel CR, Thorne CA, Campos SK, Khanna R. Novel Compounds Targeting Neuropilin Receptor 1 with Potential To Interfere with SARS-CoV-2 Virus Entry. ACS Chem Neurosci 2021;12:1299-312. [PMID: 33787218 DOI: 10.1021/acschemneuro.0c00619] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
135 Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, Sotomayor-González A, Glasner DR, Reyes KR, Gliwa AS, Reddy NP, Sanchez San Martin C, Federman S, Cheng J, Balcerek J, Taylor J, Streithorst JA, Miller S, Sreekumar B, Chen PY, Schulze-Gahmen U, Taha TY, Hayashi JM, Simoneau CR, Kumar GR, McMahon S, Lidsky PV, Xiao Y, Hemarajata P, Green NM, Espinosa A, Kath C, Haw M, Bell J, Hacker JK, Hanson C, Wadford DA, Anaya C, Ferguson D, Frankino PA, Shivram H, Lareau LF, Wyman SK, Ott M, Andino R, Chiu CY. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell 2021;184:3426-3437.e8. [PMID: 33991487 DOI: 10.1016/j.cell.2021.04.025] [Cited by in Crossref: 53] [Cited by in F6Publishing: 185] [Article Influence: 53.0] [Reference Citation Analysis]
136 Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, Aye P, Navarro MJ, Lai L, Edara VV, Röltgen K, Rogers K, Shirreff L, Ferrell DE, Wrenn S, Pettie D, Kraft JC, Miranda MC, Kepl E, Sydeman C, Brunette N, Murphy M, Fiala B, Carter L, White AG, Trisal M, Hsieh CL, Russell-Lodrigue K, Monjure C, Dufour J, Spencer S, Doyle-Meyers L, Bohm RP, Maness NJ, Roy C, Plante JA, Plante KS, Zhu A, Gorman MJ, Shin S, Shen X, Fontenot J, Gupta S, O'Hagan DT, Van Der Most R, Rappuoli R, Coffman RL, Novack D, McLellan JS, Subramaniam S, Montefiori D, Boyd SD, Flynn JL, Alter G, Villinger F, Kleanthous H, Rappaport J, Suthar MS, King NP, Veesler D, Pulendran B. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature 2021;594:253-8. [PMID: 33873199 DOI: 10.1038/s41586-021-03530-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 93] [Article Influence: 16.0] [Reference Citation Analysis]
137 Donofrio G, Franceschi V, Macchi F, Russo L, Rocci A, Marchica V, Costa F, Giuliani N, Ferrari C, Missale G. A Simplified SARS-CoV-2 Pseudovirus Neutralization Assay. Vaccines (Basel) 2021;9:389. [PMID: 33920999 DOI: 10.3390/vaccines9040389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
138 Verma S, Joshi CS, Silverstein RB, He M, Carter EB, Mysorekar IU. SARS-CoV-2 colonization of maternal and fetal cells of the human placenta promotes alteration of local renin-angiotensin system. Med (N Y) 2021;2:575-590.e5. [PMID: 33870242 DOI: 10.1016/j.medj.2021.04.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
139 Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, El-Qunni AA, Haile A, Huang K, Kinnett B, Liebeskind MJ, Liu Z, McMorrow LE, Paez D, Perantie DC, Schriefer RE, Sides SE, Thapa M, Gergely M, Abushamma S, Klebert M, Mitchell L, Nix D, Graf J, Taylor KE, Chahin S, Ciorba MA, Katz P, Matloubian M, O'Halloran JA, Presti RM, Wu GF, Whelan SPJ, Buchser WJ, Gensler LS, Nakamura MC, Ellebedy AH, Kim AHJ. Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2. medRxiv 2021:2021. [PMID: 33851176 DOI: 10.1101/2021.04.05.21254656] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 20.0] [Reference Citation Analysis]
140 Starr TN, Czudnochowski N, Zatta F, Park YJ, Liu Z, Addetia A, Pinto D, Beltramello M, Hernandez P, Greaney AJ, Marzi R, Glass WG, Zhang I, Dingens AS, Bowen JE, Wojcechowskyj JA, De Marco A, Rosen LE, Zhou J, Montiel-Ruiz M, Kaiser H, Tucker H, Housley MP, di Iulio J, Lombardo G, Agostini M, Sprugasci N, Culap K, Jaconi S, Meury M, Dellota E, Cameroni E, Croll TI, Nix JC, Havenar-Daughton C, Telenti A, Lempp FA, Pizzuto MS, Chodera JD, Hebner CM, Whelan SPJ, Virgin HW, Veesler D, Corti D, Bloom JD, Snell G. Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape. bioRxiv 2021:2021. [PMID: 33851154 DOI: 10.1101/2021.04.06.438709] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 9.0] [Reference Citation Analysis]
141 Ikegame S, Siddiquey MNA, Hung CT, Haas G, Brambilla L, Oguntuyo KY, Kowdle S, Vilardo AE, Edelstein A, Perandones C, Kamil JP, Lee B. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Res Sq 2021:rs. [PMID: 33851150 DOI: 10.21203/rs.3.rs-400230/v1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
142 Makdasi E, Levy Y, Alcalay R, Noy-Porat T, Zahavy E, Mechaly A, Epstein E, Peretz E, Cohen H, Bar-On L, Chitlaru T, Cohen O, Glinert I, Achdout H, Israely T, Rosenfeld R, Mazor O. Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope. Viruses 2021;13:566. [PMID: 33810465 DOI: 10.3390/v13040566] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
143 Schmitz AJ, Turner JS, Liu Z, Aziati ID, Chen RE, Joshi A, Bricker TL, Darling TL, Adelsberg DC, Alsoussi WB, Case JB, Lei T, Thapa M, Amanat F, O'Halloran JA, Shi PY, Presti RM, Krammer F, Bajic G, Whelan SPJ, Diamond MS, Boon ACM, Ellebedy AH. A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants. bioRxiv 2021:2021. [PMID: 33791696 DOI: 10.1101/2021.03.24.436864] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
144 Self WH, Stewart TG, Wheeler AP, El Atrouni W, Bistran-Hall AJ, Casey JD, Cataldo VD, Chappell JD, Cohn CS, Collins JB, Denison MR, de Wit M, Dixon SL, Duggal A, Edwards TL, Fontaine MJ, Ginde AA, Harkins MS, Harrington T, Harris ES, Hoda D, Ipe TS, Jaiswal SJ, Johnson NJ, Jones AE, Laguio-Vila M, Lindsell CJ, Mallada J, Mammen MJ, Metcalf RA, Middleton EA, Mucha S, O'Neal HR Jr, Pannu SR, Pulley JM, Qiao X, Raval JS, Rhoads JP, Schrager H, Shanholtz C, Shapiro NI, Schrantz SJ, Thomsen I, Vermillion KK, Bernard GR, Rice TW; Passive Immunity Trial for Our Nation (PassITON) Investigators. Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults. Trials 2021;22:221. [PMID: 33743799 DOI: 10.1186/s13063-021-05171-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
145 Murray MJ, McIntosh M, Atkinson C, Mahungu T, Wright E, Chatterton W, Gandy M, Reeves MB. Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay. J Infect 2021;82:170-7. [PMID: 33753152 DOI: 10.1016/j.jinf.2021.03.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
146 Hassan AO, Feldmann F, Zhao H, Curiel DT, Okumura A, Tang-Huau TL, Case JB, Meade-White K, Callison J, Chen RE, Lovaglio J, Hanley PW, Scott DP, Fremont DH, Feldmann H, Diamond MS. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. Cell Rep Med 2021;2:100230. [PMID: 33754147 DOI: 10.1016/j.xcrm.2021.100230] [Cited by in Crossref: 13] [Cited by in F6Publishing: 36] [Article Influence: 13.0] [Reference Citation Analysis]
147 Suryadevara N, Shrihari S, Gilchuk P, VanBlargan LA, Binshtein E, Zost SJ, Nargi RS, Sutton RE, Winkler ES, Chen EC, Fouch ME, Davidson E, Doranz BJ, Chen RE, Shi PY, Carnahan RH, Thackray LB, Diamond MS, Crowe JE Jr. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell 2021;184:2316-2331.e15. [PMID: 33773105 DOI: 10.1016/j.cell.2021.03.029] [Cited by in Crossref: 38] [Cited by in F6Publishing: 134] [Article Influence: 38.0] [Reference Citation Analysis]
148 Yu J, Li Z, He X, Gebre MS, Bondzie EA, Wan H, Jacob-Dolan C, Martinez DR, Nkolola JP, Baric RS, Barouch DH. Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays. J Virol 2021:JVI. [PMID: 33727331 DOI: 10.1128/JVI.00044-21] [Cited by in Crossref: 13] [Cited by in F6Publishing: 36] [Article Influence: 13.0] [Reference Citation Analysis]
149 Yuan Y, Yu L, Jin Z, Wang Y, Gao M, Ding H, Zhuo X, Zhu X, Gao F, Zheng X, Ying G, Xu X, Kong Q, Lu S, Lv H. Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020. Front Cell Infect Microbiol 2021;11:650487. [PMID: 33796489 DOI: 10.3389/fcimb.2021.650487] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
150 McCallum M, De Marco A, Lempp FA, Tortorici MA, Pinto D, Walls AC, Beltramello M, Chen A, Liu Z, Zatta F, Zepeda S, di Iulio J, Bowen JE, Montiel-Ruiz M, Zhou J, Rosen LE, Bianchi S, Guarino B, Fregni CS, Abdelnabi R, Foo SC, Rothlauf PW, Bloyet LM, Benigni F, Cameroni E, Neyts J, Riva A, Snell G, Telenti A, Whelan SPJ, Virgin HW, Corti D, Pizzuto MS, Veesler D. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 2021;184:2332-2347.e16. [PMID: 33761326 DOI: 10.1016/j.cell.2021.03.028] [Cited by in Crossref: 103] [Cited by in F6Publishing: 313] [Article Influence: 103.0] [Reference Citation Analysis]
151 Collier DA, De Marco A, Ferreira IATM, Meng B, Datir RP, Walls AC, Kemp SA, Bassi J, Pinto D, Silacci-Fregni C, Bianchi S, Tortorici MA, Bowen J, Culap K, Jaconi S, Cameroni E, Snell G, Pizzuto MS, Pellanda AF, Garzoni C, Riva A, Elmer A, Kingston N, Graves B, McCoy LE, Smith KGC, Bradley JR, Temperton N, Ceron-Gutierrez L, Barcenas-Morales G, Harvey W, Virgin HW, Lanzavecchia A, Piccoli L, Doffinger R, Wills M, Veesler D, Corti D, Gupta RK; CITIID-NIHR BioResource COVID-19 Collaboration., COVID-19 Genomics UK (COG-UK) Consortium. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature 2021;593:136-41. [PMID: 33706364 DOI: 10.1038/s41586-021-03412-7] [Cited by in Crossref: 148] [Cited by in F6Publishing: 361] [Article Influence: 148.0] [Reference Citation Analysis]
152 Balkrishna A, Pokhrel S, Singh H, Joshi M, Mulay VP, Haldar S, Varshney A. Withanone from Withania somnifera Attenuates SARS-CoV-2 RBD and Host ACE2 Interactions to Rescue Spike Protein Induced Pathologies in Humanized Zebrafish Model. Drug Des Devel Ther 2021;15:1111-33. [PMID: 33737804 DOI: 10.2147/DDDT.S292805] [Cited by in Crossref: 8] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
153 Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, Sotomayor-González A, Glasner DR, Reyes KR, Gliwa AS, Reddy NP, Sanchez San Martin C, Federman S, Cheng J, Balcerek J, Taylor J, Streithorst JA, Miller S, Kumar GR, Sreekumar B, Chen PY, Schulze-Gahmen U, Taha TY, Hayashi J, Simoneau CR, McMahon S, Lidsky PV, Xiao Y, Hemarajata P, Green NM, Espinosa A, Kath C, Haw M, Bell J, Hacker JK, Hanson C, Wadford DA, Anaya C, Ferguson D, Lareau LF, Frankino PA, Shivram H, Wyman SK, Ott M, Andino R, Chiu CY. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv 2021:2021. [PMID: 33758899 DOI: 10.1101/2021.03.07.21252647] [Cited by in Crossref: 61] [Cited by in F6Publishing: 29] [Article Influence: 61.0] [Reference Citation Analysis]
154 Tian L, Elsheikh EB, Patrone PN, Kearsley AJ, Gaigalas AK, Inwood S, Lin-Gibson S, Esposito D, Wang L. Towards Quantitative and Standardized Serological and Neutralization Assays for COVID-19. Int J Mol Sci 2021;22:2723. [PMID: 33800363 DOI: 10.3390/ijms22052723] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
155 Sakharkar M, Rappazzo CG, Wieland-Alter WF, Hsieh CL, Wrapp D, Esterman ES, Kaku CI, Wec AZ, Geoghegan JC, McLellan JS, Connor RI, Wright PF, Walker LM. Prolonged evolution of the human B cell response to SARS-CoV-2 infection. Sci Immunol 2021;6:eabg6916. [PMID: 33622975 DOI: 10.1126/sciimmunol.abg6916] [Cited by in Crossref: 28] [Cited by in F6Publishing: 68] [Article Influence: 28.0] [Reference Citation Analysis]
156 Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, Liu J, Errico JM, Xie X, Suryadevara N, Gilchuk P, Zost SJ, Tahan S, Droit L, Turner JS, Kim W, Schmitz AJ, Thapa M, Wang D, Boon ACM, Presti RM, O'Halloran JA, Kim AHJ, Deepak P, Pinto D, Fremont DH, Crowe JE Jr, Corti D, Virgin HW, Ellebedy AH, Shi PY, Diamond MS. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med 2021;27:717-26. [PMID: 33664494 DOI: 10.1038/s41591-021-01294-w] [Cited by in Crossref: 151] [Cited by in F6Publishing: 443] [Article Influence: 151.0] [Reference Citation Analysis]
157 Lai CY, To A, Wong TAS, Lieberman MM, Clements DE, Senda JT, Ball AH, Pessaint L, Andersen H, Donini O, Lehrer AT. Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice. bioRxiv 2021:2021. [PMID: 33688645 DOI: 10.1101/2021.03.02.433614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Self WH, Stewart TG, Wheeler AP, El Atrouni W, Bistran-Hall AJ, Casey JD, Cataldo VD, Chappell JD, Cohn CS, Collins JB, Denison MR, de Wit M, Dixon SL, Duggal A, Edwards TL, Fontaine MJ, Ginde AA, Harkins MS, Harrington T, Harris ES, Hoda D, Ipe TS, Jaiswal SJ, Johnson NJ, Jones AE, Laguio-Vila M, Lindsell CJ, Mallada J, Mammen MJ, Metcalf RA, Middleton EA, Mucha S, O'Neal HR, Pannu SR, Pulley JM, Qiao X, Raval JS, Rhoads JP, Schrager H, Shanholtz C, Shapiro NI, Schrantz SJ, Thomsen I, Vermillion KK, Bernard GR, Rice TW. Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults. Res Sq 2021:rs. [PMID: 33688640 DOI: 10.21203/rs.3.rs-227796/v1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Puray-Chavez M, LaPak KM, Schrank TP, Elliott JL, Bhatt DP, Agajanian MJ, Jasuja R, Lawson DQ, Davis K, Rothlauf PW, Jo H, Lee N, Tenneti K, Eschbach JE, Mugisha CS, Vuong HR, Bailey AL, Hayes DN, Whelan SPJ, Horani A, Brody SL, Goldfarb D, Major MB, Kutluay SB. Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell. bioRxiv 2021:2021. [PMID: 33688646 DOI: 10.1101/2021.03.01.433431] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
160 Dong J, Zost S, Greaney A, Starr TN, Dingens AS, Chen EC, Chen R, Case B, Sutton R, Gilchuk P, Rodriguez J, Armstrong E, Gainza C, Nargi R, Binshtein E, Xie X, Zhang X, Shi PY, Logue J, Weston S, McGrath M, Frieman M, Brady T, Tuffy K, Bright H, Loo YM, McvTamney P, Esser M, Carnahan R, Diamond M, Bloom J, Crowe JE. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. bioRxiv 2021:2021. [PMID: 33532768 DOI: 10.1101/2021.01.27.428529] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 20.0] [Reference Citation Analysis]
161 Crawford KHD, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, Shuey K, Casto AM, Fiala B, Wrenn S, Pettie D, King NP, Greninger AL, Chu HY, Bloom JD. Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Infect Dis 2021;223:197-205. [PMID: 33535236 DOI: 10.1093/infdis/jiaa618] [Cited by in Crossref: 53] [Cited by in F6Publishing: 105] [Article Influence: 53.0] [Reference Citation Analysis]
162 Kang YF, Sun C, Zhuang Z, Yuan RY, Zheng Q, Li JP, Zhou PP, Chen XC, Liu Z, Zhang X, Yu XH, Kong XW, Zhu QY, Zhong Q, Xu M, Zhong NS, Zeng YX, Feng GK, Ke C, Zhao JC, Zeng MS. Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates. ACS Nano 2021;15:2738-52. [PMID: 33464829 DOI: 10.1021/acsnano.0c08379] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 60.0] [Reference Citation Analysis]
163 Zhang X, Liu Y, Liu J, Bailey AL, Plante KS, Plante JA, Zou J, Xia H, Bopp NE, Aguilar PV, Ren P, Menachery VD, Diamond MS, Weaver SC, Xie X, Shi PY. A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence. Cell 2021;184:2229-2238.e13. [PMID: 33691138 DOI: 10.1016/j.cell.2021.02.044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
164 Collier DA, De Marco A, Ferreira IATM, Meng B, Datir R, Walls AC, Kemp S SA, Bassi J, Pinto D, Fregni CS, Bianchi S, Tortorici MA, Bowen J, Culap K, Jaconi S, Cameroni E, Snell G, Pizzuto MS, Pellanda AF, Garzoni C, Riva A, Elmer A, Kingston N, Graves B, McCoy LE, Smith KG, Bradley JR, Temperton N, Ceron-Gutierrez L L, Barcenas-Morales G, Harvey W, Virgin HW, Lanzavecchia A, Piccoli L, Doffinger R, Wills M, Veesler D, Corti D, Gupta RK; CITIID-NIHR BioResource COVID-19 Collaboration., COVID-19 Genomics UK (COG-UK) consortium. SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies. medRxiv 2021:2021. [PMID: 33619509 DOI: 10.1101/2021.01.19.21249840] [Cited by in Crossref: 55] [Cited by in F6Publishing: 15] [Article Influence: 55.0] [Reference Citation Analysis]
165 S Arunachalam P, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, Aye P, Navarro MJ, Lai L, Edara VV, Roltgen K, Rogers K, Shirreff L, Ferrell DE, Wrenn S, Pettie D, Kraft JC, Miranda MC, Kepl E, Sydeman C, Brunette N, Murphy M, Fiala B, Carter L, White AG, Trisal M, Hsieh CL, Russell-Lodrigue K, Monjure C, Dufour J, Doyle-Meyer L, Bohm RB, Maness NJ, Roy C, Plante JA, Plante KS, Zhu A, Gorman MJ, Shin S, Shen X, Fontenot J, Gupta S, O Hagan DT, Most RV, Rappuoli R, Coffman RL, Novack D, McLellan JS, Subramaniam S, Montefiori D, Boyd SD, Flynn JL, Alter G, Villinger F, Kleanthous H, Rappaport J, Suthar M, King NP, Veesler D, Pulendran B. Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates. bioRxiv 2021:2021. [PMID: 33594366 DOI: 10.1101/2021.02.10.430696] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
166 Rosenfeld R, Noy-Porat T, Mechaly A, Makdasi E, Levy Y, Alcalay R, Falach R, Aftalion M, Epstein E, Gur D, Chitlaru T, Vitner EB, Melamed S, Politi B, Zauberman A, Lazar S, Beth-Din A, Evgy Y, Yitzhaki S, Shapira SC, Israely T, Mazor O. Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody. Nat Commun 2021;12:944. [PMID: 33574228 DOI: 10.1038/s41467-021-21239-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 30] [Article Influence: 20.0] [Reference Citation Analysis]
167 Diamond M, Chen R, Xie X, Case J, Zhang X, VanBlargan L, Liu Y, Liu J, Errico J, Winkler E, Suryadevara N, Tahan S, Turner J, Kim W, Schmitz A, Thapa M, Wang D, Boon A, Pinto D, Presti R, O'Halloran J, Kim A, Deepak P, Fremont D, Corti D, Virgin H, Crowe J, Droit L, Ellebedy A, Shi PY, Gilchuk P. SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies. Res Sq 2021:rs. [PMID: 33594356 DOI: 10.21203/rs.3.rs-228079/v1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 6] [Article Influence: 34.0] [Reference Citation Analysis]
168 Azad T, Singaravelu R, Taha Z, Jamieson TR, Boulton S, Crupi MJF, Martin NT, Brown EEF, Poutou J, Ghahremani M, Pelin A, Nouri K, Rezaei R, Marshall CB, Enomoto M, Arulanandam R, Alluqmani N, Samson R, Gingras AC, Cameron DW, Greer PA, Ilkow CS, Diallo JS, Bell JC. Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry. Mol Ther 2021;29:1984-2000. [PMID: 33578036 DOI: 10.1016/j.ymthe.2021.02.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
169 Batty CJ, Heise MT, Bachelder EM, Ainslie KM. Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. Adv Drug Deliv Rev 2021;169:168-89. [PMID: 33316346 DOI: 10.1016/j.addr.2020.12.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 37.0] [Reference Citation Analysis]
170 Muik A, Wallisch AK, Sänger B, Swanson KA, Mühl J, Chen W, Cai H, Maurus D, Sarkar R, Türeci Ö, Dormitzer PR, Şahin U. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science 2021;371:1152-3. [PMID: 33514629 DOI: 10.1126/science.abg6105] [Cited by in Crossref: 150] [Cited by in F6Publishing: 307] [Article Influence: 150.0] [Reference Citation Analysis]
171 Liu Z, VanBlargan LA, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, Zhao H, Errico JM, Theel ES, Liebeskind MJ, Alford B, Buchser WJ, Ellebedy AH, Fremont DH, Diamond MS, Whelan SPJ. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 2021;29:477-488.e4. [PMID: 33535027 DOI: 10.1016/j.chom.2021.01.014] [Cited by in Crossref: 159] [Cited by in F6Publishing: 375] [Article Influence: 159.0] [Reference Citation Analysis]
172 Powell AE, Zhang K, Sanyal M, Tang S, Weidenbacher PA, Li S, Pham TD, Pak JE, Chiu W, Kim PS. A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. ACS Cent Sci 2021;7:183-99. [PMID: 33527087 DOI: 10.1021/acscentsci.0c01405] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 58.0] [Reference Citation Analysis]
173 Hassan AO, Feldmann F, Zhao H, Curiel DT, Okumura A, Tang-Huau TL, Case JB, Meade-White K, Callison J, Lovaglio J, Hanley PW, Scott DP, Fremont DH, Feldmann H, Diamond MS. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. bioRxiv 2021:2021. [PMID: 33532770 DOI: 10.1101/2021.01.26.428251] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
174 Brocato RL, Kwilas SA, Kim RK, Zeng X, Principe LM, Smith JM, Hooper JW. Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters. NPJ Vaccines 2021;6:16. [PMID: 33495468 DOI: 10.1038/s41541-020-00279-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
175 Jin RU, Brown JW, Li QK, Bayguinov PO, Wang JS, Mills JC. Tropism of Severe Acute Respiratory Syndrome Coronavirus 2 for Barrett's Esophagus May Increase Susceptibility to Developing Coronavirus Disease 2019. Gastroenterology 2021;160:2165-2168.e4. [PMID: 33484686 DOI: 10.1053/j.gastro.2021.01.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
176 Suryadevara N, Shrihari S, Gilchuk P, VanBlargan LA, Binshtein E, Zost SJ, Nargi RS, Sutton RE, Winkler ES, Chen EC, Fouch ME, Davidson E, Doranz BJ, Carnahan RH, Thackray LB, Diamond MS, Crowe JE. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. bioRxiv 2021:2021. [PMID: 33501445 DOI: 10.1101/2021.01.19.427324] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 17.0] [Reference Citation Analysis]
177 Zhang X, Liu Y, Liu J, Bailey AL, Plante KS, Plante JA, Zou J, Xia H, Bopp N, Aguilar P, Ren P, Menachery VD, Diamond MS, Weaver SC, Xie X, Shi PY. A trans -complementation system for SARS-CoV-2. bioRxiv 2021:2021. [PMID: 33501436 DOI: 10.1101/2021.01.16.426970] [Reference Citation Analysis]
178 McCallum M, Marco A, Lempp F, Tortorici MA, Pinto D, Walls AC, Beltramello M, Chen A, Liu Z, Zatta F, Zepeda S, di Iulio J, Bowen JE, Montiel-Ruiz M, Zhou J, Rosen LE, Bianchi S, Guarino B, Fregni CS, Abdelnabi R, Caroline Foo SY, Rothlauf PW, Bloyet LM, Benigni F, Cameroni E, Neyts J, Riva A, Snell G, Telenti A, Whelan SPJ, Virgin HW, Corti D, Pizzuto MS, Veesler D. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. bioRxiv 2021:2021. [PMID: 33469588 DOI: 10.1101/2021.01.14.426475] [Cited by in Crossref: 34] [Cited by in F6Publishing: 8] [Article Influence: 34.0] [Reference Citation Analysis]
179 Gould JR, Qiu S, Shang Q, Dokland T, Ogino T, Petit CM, Green TJ. Consequences of Phosphorylation in a Mononegavirales Polymerase-Cofactor System. J Virol 2021:JVI. [PMID: 33441337 DOI: 10.1128/JVI.02180-20] [Reference Citation Analysis]
180 Tani H, Kimura M, Tan L, Yoshida Y, Ozawa T, Kishi H, Fukushi S, Saijo M, Sano K, Suzuki T, Kawasuji H, Ueno A, Miyajima Y, Fukui Y, Sakamaki I, Yamamoto Y, Morinaga Y. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein. Virol J 2021;18:16. [PMID: 33435994 DOI: 10.1186/s12985-021-01490-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
181 Koenig PA, Das H, Liu H, Kümmerer BM, Gohr FN, Jenster LM, Schiffelers LDJ, Tesfamariam YM, Uchima M, Wuerth JD, Gatterdam K, Ruetalo N, Christensen MH, Fandrey CI, Normann S, Tödtmann JMP, Pritzl S, Hanke L, Boos J, Yuan M, Zhu X, Schmid-Burgk JL, Kato H, Schindler M, Wilson IA, Geyer M, Ludwig KU, Hällberg BM, Wu NC, Schmidt FI. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Science 2021;371:eabe6230. [PMID: 33436526 DOI: 10.1126/science.abe6230] [Cited by in Crossref: 81] [Cited by in F6Publishing: 150] [Article Influence: 81.0] [Reference Citation Analysis]
182 Liu Z, VanBlargan LA, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, Zhao H, Errico JM, Theel ES, Liebeskind MJ, Alford B, Buchser WJ, Ellebedy AH, Fremont DH, Diamond MS, Whelan SPJ. Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. bioRxiv 2021:2020. [PMID: 33442690 DOI: 10.1101/2020.11.06.372037] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 26.0] [Reference Citation Analysis]
183 Turner JS, Day A, Alsoussi WB, Liu Z, O'Halloran JA, Presti RM, Patterson BK, Whelan SPJ, Ellebedy AH, Mudd PA. SARS-CoV-2 Viral RNA Shedding for More Than 87 Days in an Individual With an Impaired CD8+ T Cell Response. Front Immunol 2020;11:618402. [PMID: 33488630 DOI: 10.3389/fimmu.2020.618402] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
184 Hashizume M, Gonzalez G, Ono C, Takashima A, Iwasaki M. Population-Specific ACE2 Single-Nucleotide Polymorphisms Have Limited Impact on SARS-CoV-2 Infectivity In Vitro. Viruses 2021;13:67. [PMID: 33418950 DOI: 10.3390/v13010067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
185 Oz M, Lorke DE. Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury. Biomed Pharmacother 2021;136:111193. [PMID: 33461019 DOI: 10.1016/j.biopha.2020.111193] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
186 Miersch S, Li Z, Saberianfar R, Ustav M, Case JB, Blazer L, Chen C, Ye W, Pavlenco A, Gorelik M, Perez JG, Subramania S, Singh S, Ploder L, Ganaie S, Chen RE, Leung DW, Pandolfi PP, Novelli G, Matusali G, Colavita F, Capobianchi MR, Jain S, Gupta JB, Amarasinghe GK, Diamond MS, Rini J, Sidhu SS. Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations. bioRxiv 2020:2020. [PMID: 33398270 DOI: 10.1101/2020.10.31.362848] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
187 Havranek KE, Jimenez AR, Acciani MD, Lay Mendoza MF, Reyes Ballista JM, Diaz DA, Brindley MA. SARS-CoV-2 Spike Alterations Enhance Pseudoparticle Titers and Replication-Competent VSV-SARS-CoV-2 Virus. Viruses 2020;12:E1465. [PMID: 33353101 DOI: 10.3390/v12121465] [Cited by in Crossref: 3] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
188 Lay Mendoza MF, Acciani MD, Levit CN, Santa Maria C, Brindley MA. Monitoring Viral Entry in Real-Time Using a Luciferase Recombinant Vesicular Stomatitis Virus Producing SARS-CoV-2, EBOV, LASV, CHIKV, and VSV Glycoproteins. Viruses 2020;12:E1457. [PMID: 33348746 DOI: 10.3390/v12121457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
189 Yahalom-Ronen Y, Tamir H, Melamed S, Politi B, Shifman O, Achdout H, Vitner EB, Israeli O, Milrot E, Stein D, Cohen-Gihon I, Lazar S, Gutman H, Glinert I, Cherry L, Vagima Y, Lazar S, Weiss S, Ben-Shmuel A, Avraham R, Puni R, Lupu E, Bar-David E, Sittner A, Erez N, Zichel R, Mamroud E, Mazor O, Levy H, Laskar O, Yitzhaki S, Shapira SC, Zvi A, Beth-Din A, Paran N, Israely T. A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge. Nat Commun 2020;11:6402. [PMID: 33328475 DOI: 10.1038/s41467-020-20228-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 101] [Article Influence: 21.0] [Reference Citation Analysis]
190 Henderson JP. What are protective antibody responses to pandemic SARS-CoV-2? J Clin Invest 2020;130:6232-4. [PMID: 33055417 DOI: 10.1172/JCI143466] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
191 Tada T, Fan C, Chen JS, Kaur R, Stapleford KA, Gristick H, Dcosta BM, Wilen CB, Nimigean CM, Landau NR. An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2. Cell Rep 2020;33:108528. [PMID: 33326798 DOI: 10.1016/j.celrep.2020.108528] [Cited by in Crossref: 16] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
192 Zang R, Case JB, Yutuc E, Ma X, Shen S, Gomez Castro MF, Liu Z, Zeng Q, Zhao H, Son J, Rothlauf PW, Kreutzberger AJB, Hou G, Zhang H, Bose S, Wang X, Vahey MD, Mani K, Griffiths WJ, Kirchhausen T, Fremont DH, Guo H, Diwan A, Wang Y, Diamond MS, Whelan SPJ, Ding S. Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion. Proc Natl Acad Sci U S A 2020;117:32105-13. [PMID: 33239446 DOI: 10.1073/pnas.2012197117] [Cited by in Crossref: 43] [Cited by in F6Publishing: 86] [Article Influence: 21.5] [Reference Citation Analysis]
193 Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, Hilton SK, Huddleston J, Eguia R, Crawford KHD, Dingens AS, Nargi RS, Sutton RE, Suryadevara N, Rothlauf PW, Liu Z, Whelan SPJ, Carnahan RH, Crowe JE Jr, Bloom JD. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host Microbe 2021;29:44-57.e9. [PMID: 33259788 DOI: 10.1016/j.chom.2020.11.007] [Cited by in Crossref: 259] [Cited by in F6Publishing: 425] [Article Influence: 129.5] [Reference Citation Analysis]
194 Zhou L, Huntington K, Zhang S, Carlsen L, So EY, Parker C, Sahin I, Safran H, Kamle S, Lee CM, Geun Lee C, A Elias J, S Campbell K, T Naik M, J Atwood W, Youssef E, A Pachter J, Navaraj A, A Seyhan A, Liang O, El-Deiry WS. MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection. Oncotarget 2020;11:4201-23. [PMID: 33245731 DOI: 10.18632/oncotarget.27799] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
195 Khoury DS, Wheatley AK, Ramuta MD, Reynaldi A, Cromer D, Subbarao K, O'Connor DH, Kent SJ, Davenport MP. Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. Nat Rev Immunol 2020;20:727-38. [PMID: 33139888 DOI: 10.1038/s41577-020-00471-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 56] [Article Influence: 12.5] [Reference Citation Analysis]
196 Li Y, Wang H, Tang X, Fang S, Ma D, Du C, Wang Y, Pan H, Yao W, Zhang R, Zou X, Zheng J, Xu L, Farzan M, Zhong G. SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig. J Virol 2020;94:e01283-20. [PMID: 32847856 DOI: 10.1128/JVI.01283-20] [Cited by in Crossref: 30] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
197 Glasgow A, Glasgow J, Limonta D, Solomon P, Lui I, Zhang Y, Nix MA, Rettko NJ, Zha S, Yamin R, Kao K, Rosenberg OS, Ravetch JV, Wiita AP, Leung KK, Lim SA, Zhou XX, Hobman TC, Kortemme T, Wells JA. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. Proc Natl Acad Sci U S A 2020;117:28046-55. [PMID: 33093202 DOI: 10.1073/pnas.2016093117] [Cited by in Crossref: 64] [Cited by in F6Publishing: 95] [Article Influence: 32.0] [Reference Citation Analysis]
198 Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, Hilton SK, Huddleston J, Eguia R, Crawford KHD, Dingens AS, Nargi RS, Sutton RE, Suryadevara N, Rothlauf PW, Liu Z, Whelan SPJ, Carnahan RH, Crowe JE Jr, Bloom JD. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. bioRxiv 2020:2020. [PMID: 32935107 DOI: 10.1101/2020.09.10.292078] [Cited by in Crossref: 31] [Cited by in F6Publishing: 5] [Article Influence: 15.5] [Reference Citation Analysis]
199 Tortorici MA, Beltramello M, Lempp FA, Pinto D, Dang HV, Rosen LE, McCallum M, Bowen J, Minola A, Jaconi S, Zatta F, De Marco A, Guarino B, Bianchi S, Lauron EJ, Tucker H, Zhou J, Peter A, Havenar-Daughton C, Wojcechowskyj JA, Case JB, Chen RE, Kaiser H, Montiel-Ruiz M, Meury M, Czudnochowski N, Spreafico R, Dillen J, Ng C, Sprugasci N, Culap K, Benigni F, Abdelnabi R, Foo SC, Schmid MA, Cameroni E, Riva A, Gabrieli A, Galli M, Pizzuto MS, Neyts J, Diamond MS, Virgin HW, Snell G, Corti D, Fink K, Veesler D. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science 2020;370:950-7. [PMID: 32972994 DOI: 10.1126/science.abe3354] [Cited by in Crossref: 166] [Cited by in F6Publishing: 274] [Article Influence: 83.0] [Reference Citation Analysis]
200 Perez-Miller S, Patek M, Moutal A, Cabel CR, Thorne CA, Campos SK, Khanna R. In silico identification and validation of inhibitors of the interaction between neuropilin receptor 1 and SARS-CoV-2 Spike protein. bioRxiv 2020:2020. [PMID: 32995772 DOI: 10.1101/2020.09.22.308783] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
201 Cimolai N. A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19. SN Compr Clin Med 2020;:1-8. [PMID: 32984765 DOI: 10.1007/s42399-020-00533-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
202 Coughlan L. Snatching the Crown from SARS-CoV-2. Cell Host Microbe 2020;28:360-3. [PMID: 32910919 DOI: 10.1016/j.chom.2020.08.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
203 Hyseni I, Molesti E, Benincasa L, Piu P, Casa E, Temperton NJ, Manenti A, Montomoli E. Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays. Viruses 2020;12:E1011. [PMID: 32927639 DOI: 10.3390/v12091011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 9.5] [Reference Citation Analysis]
204 Kumar V. Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. Int Immunopharmacol 2020;88:106980. [PMID: 33182073 DOI: 10.1016/j.intimp.2020.106980] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
205 Li W, Schäfer A, Kulkarni SS, Liu X, Martinez DR, Chen C, Sun Z, Leist SR, Drelich A, Zhang L, Ura ML, Berezuk A, Chittori S, Leopold K, Mannar D, Srivastava SS, Zhu X, Peterson EC, Tseng CT, Mellors JW, Falzarano D, Subramaniam S, Baric RS, Dimitrov DS. High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models. Cell 2020;183:429-441.e16. [PMID: 32941803 DOI: 10.1016/j.cell.2020.09.007] [Cited by in Crossref: 49] [Cited by in F6Publishing: 57] [Article Influence: 24.5] [Reference Citation Analysis]
206 Almahboub SA, Algaissi A, Alfaleh MA, ElAssouli MZ, Hashem AM. Evaluation of Neutralizing Antibodies Against Highly Pathogenic Coronaviruses: A Detailed Protocol for a Rapid Evaluation of Neutralizing Antibodies Using Vesicular Stomatitis Virus Pseudovirus-Based Assay. Front Microbiol 2020;11:2020. [PMID: 33013745 DOI: 10.3389/fmicb.2020.02020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
207 Zhou L, Huntington K, Zhang S, Carlsen L, So EY, Parker C, Sahin I, Safran H, Kamle S, Lee CM, Lee CG, Elias JA, Campbell KS, Naik MT, Atwood WJ, Youssef E, Pachter JA, Navaraj A, Seyhan AA, Liang O, El-Deiry WS. Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells. bioRxiv 2020:2020. [PMID: 32793908 DOI: 10.1101/2020.08.02.230839] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
208 Resnick SJ, Iketani S, Hong SJ, Zask A, Liu H, Kim S, Melore S, Nair MS, Huang Y, Tay NES, Rovis T, Yang HW, Stockwell BR, Ho DD, Chavez A. A simplified cell-based assay to identify coronavirus 3CL protease inhibitors. bioRxiv 2020:2020. [PMID: 32869020 DOI: 10.1101/2020.08.29.272864] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
209 Powell AE, Zhang K, Sanyal M, Tang S, Weidenbacher PA, Li S, Pham TD, Pak JE, Chiu W, Kim PS. A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice. bioRxiv 2020:2020. [PMID: 32869030 DOI: 10.1101/2020.08.28.272518] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
210 Klimstra WB, Tilston-Lunel NL, Nambulli S, Boslett J, McMillen CM, Gilliland T, Dunn MD, Sun C, Wheeler SE, Wells A, Hartman AL, McElroy AK, Reed DS, Rennick LJ, Duprex WP. SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients. J Gen Virol 2020;101:1156-69. [PMID: 32821033 DOI: 10.1099/jgv.0.001481] [Cited by in Crossref: 56] [Cited by in F6Publishing: 79] [Article Influence: 28.0] [Reference Citation Analysis]
211 Hassan AO, Kafai NM, Dmitriev IP, Fox JM, Smith BK, Harvey IB, Chen RE, Winkler ES, Wessel AW, Case JB, Kashentseva E, McCune BT, Bailey AL, Zhao H, VanBlargan LA, Dai YN, Ma M, Adams LJ, Shrihari S, Danis JE, Gralinski LE, Hou YJ, Schäfer A, Kim AS, Keeler SP, Weiskopf D, Baric RS, Holtzman MJ, Fremont DH, Curiel DT, Diamond MS. A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. Cell 2020;183:169-184.e13. [PMID: 32931734 DOI: 10.1016/j.cell.2020.08.026] [Cited by in Crossref: 124] [Cited by in F6Publishing: 215] [Article Influence: 62.0] [Reference Citation Analysis]
212 Moore JP, Klasse PJ. COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds. J Virol 2020;94:e01083-20. [PMID: 32591466 DOI: 10.1128/JVI.01083-20] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 23.5] [Reference Citation Analysis]
213 Glasgow A, Glasgow J, Limonta D, Solomon P, Lui I, Zhang Y, Nix MA, Rettko NJ, Lim SA, Zha S, Yamin R, Kao K, Rosenberg OS, Ravetch JV, Wiita AP, Leung KK, Zhou XX, Hobman TC, Kortemme T, Wells JA. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. bioRxiv 2020:2020. [PMID: 32766586 DOI: 10.1101/2020.07.31.231746] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
214 Case JB, Rothlauf PW, Chen RE, Kafai NM, Fox JM, Smith BK, Shrihari S, McCune BT, Harvey IB, Keeler SP, Bloyet LM, Zhao H, Ma M, Adams LJ, Winkler ES, Holtzman MJ, Fremont DH, Whelan SPJ, Diamond MS. Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. Cell Host Microbe 2020;28:465-474.e4. [PMID: 32798445 DOI: 10.1016/j.chom.2020.07.018] [Cited by in Crossref: 62] [Cited by in F6Publishing: 101] [Article Influence: 31.0] [Reference Citation Analysis]
215 Dieterle ME, Haslwanter D, Bortz RH 3rd, Wirchnianski AS, Lasso G, Vergnolle O, Abbasi SA, Fels JM, Laudermilch E, Florez C, Mengotto A, Kimmel D, Malonis RJ, Georgiev G, Quiroz J, Barnhill J, Pirofski LA, Daily JP, Dye JM, Lai JR, Herbert AS, Chandran K, Jangra RK. A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition. Cell Host Microbe 2020;28:486-496.e6. [PMID: 32738193 DOI: 10.1016/j.chom.2020.06.020] [Cited by in Crossref: 53] [Cited by in F6Publishing: 92] [Article Influence: 26.5] [Reference Citation Analysis]
216 [DOI: 10.1101/2020.07.01.182220] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
217 [DOI: 10.1101/2020.12.14.422555] [Cited by in Crossref: 100] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
218 [DOI: 10.1101/2020.08.06.20169367] [Cited by in Crossref: 44] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
219 [DOI: 10.1101/2020.11.03.366138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
220 [DOI: 10.1101/2021.02.06.430072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
221 [DOI: 10.1101/2021.01.18.426984] [Cited by in Crossref: 37] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
222 [DOI: 10.1101/2020.10.09.20207464] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Reference Citation Analysis]